MERCK
MRKMerck & Co., Inc. is an American multinational pharmaceutical company headquartered in Rahway, New Jersey. The company does business as Merck Sharp & Dohme or MSD outside the United States and Canada. The company is ranked fifth on the list of largest biomedical companies by revenue.
Drugs in Pipeline
705
Phase 3 Programs
447
Upcoming Catalysts
50
Next Catalyst
This month
Market Overview
Stock performance and key metrics
63 upcoming, 2 past
Pembrolizumab (+) Berahyaluronidase alfa Phase 3 Results Expected
Primary completion for Pembrolizumab (+) Berahyaluronidase alfa trial (NCT06698042) in Lung Cancer
Auto-detected: positive
Source62 more catalysts beyond 14 days
Start a 7-day free trial to see all upcoming catalysts
Lamivudine
HIV Infections
RotaTeq™, rotavirus vaccine, live, oral, pentavalent
Rotavirus Infections
Quadrivalent Human Papillomavirus (HPV, Types 6, 11, 16, 18) Recombinant Vaccine (Gardasil®)
Papillomavirus Infections
Infliximab + methotrexate (IFX + MTX)
Arthritis, Psoriatic
Rebif New Formulation + prophylactic Ibuprofen
Relapsing Multiple Sclerosis
PPSV23
Pneumococcal Disease
Boceprevir
Chronic Hepatitis C Genotype 1
Esmirtazapine
Insomnia
hydrochlorothiazide (HCTZ)
Hypertension
PNEUMOVAX™23
Pneumococcal Infections
Cetuximab + Platinum (Cisplatin or Carboplatin) + 5Fluorouracil (5-FU)
Head and Neck Cancer
Ertapenem sodium
Infection; Diabetic Foot
MK0826, ertapenem sodium / Duration of Treatment: 14 Days
Infection
Prednisone
Prostatic Neoplasms
pneumococcal 23v polysaccharide vaccine
Pneumococcal Infection
niacin (+) laropiprant (+) simvastatin
Primary Hypercholesterolemia
Modified Process Hepatitis B Vaccine (Experimental)
Hepatitis B
Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL™)
Papillomavirus Infections
V212
Herpes Zoster
Dexamethasone 4 mg
Non-Small-Cell Lung Carcinoma
Combination of pegylated interferon alfa-2b (PEG-Intron®) and ribavirin (Rebetol®)
Hepatitis C, Chronic
Open-label Metformin
Type 2 Diabetes
Olaparib
Ovarian Cancer
Lantus™
Type 2 Diabetes Mellitus
Raptiva
Moderate to Severe Psoriasis
Pembrolizumab 400 mg
Small Cell Lung Cancer
mRNA-1273 Vaccine
Papillomavirus Infections
docetaxel
Endometrial Neoplasms
Rescue Medications
Cervical Cancer
MTX
Arthritis, Rheumatoid
V501, Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine
Cervical Cancer
V920 Consistency Lot A
Prevention of Ebola Infection
Peginterferon alfa-2a
Hepatitis C, Chronic
Letermovir
Cytomegalovirus Infection
Sacituzumab tirumotecan
Colorectal Cancer
V232 Modified Process Hepatitis B Vaccine: Lot A
Hepatitis B Infection
PCV13
Pneumococcal Infections
Varicella Virus Vaccine Live (2007 Process) (Oka/Merck)
Varicella
Ribavirin
Hepatitis C
Anacetrapib 100 mg
Hypercholesterolemia
Tobramycin
Bacterial Conjunctivitis
Pegylated interferon alfa-2b
Hepatitis C
Basal Insulin
Type 2 Diabetes Mellitus
0.9% sodium chloride (NaCl)
Anesthesia
sac-TMT
Non-small Cell Lung Cancer
Grazoprevir 100 mg/Elbasvir 50 mg FDC tablet (MK-5172A)
Chronic Hepatitis C
Org 50081
Insomnia
HBVAXPRO™
Hepatitis B
VARIVAX™
Varicella
SC Tulisokibart
Ulcerative Colitis
Insulin
Type 2 Diabetes Mellitus
Vericiguat
Heart Failure
DAPTACEL™
Bacterial Infections
etoposide
Carcinoma, Non-Small-Cell Lung
IMI/REL FDC
Hospital-Acquired Bacterial Pneumonia
sitagliptin 100 mg q.d./pioglitazone 30 mg q.d
Type 2 Diabetes Mellitus
Vicriviroc
HIV Infections
Molnupiravir
Coronavirus Disease (COVID-19)
losartan potassium + hydrochlorothiazide + amlodipine besylate (MK-0954E)
Hypertension
ertapenem sodium (MK0826)
Urinary Tract Infection
Pegylated liposomal doxorubicin (SCH 200746)
Breast Cancer
Enzalutamide
Metastatic Hormone-Sensitive Prostate Cancer
peginterferon alfa-2b (SCH 54031)
Chronic Hepatitis C
Induction dose of (a) infliximab followed by combination of (b) pegylated interferon alfa-2b and (c) ribavirin
Hepatitis C, Chronic
Pembrolizumab SC
Non-Small Cell Lung Cancer
ISL
Human Immunodeficiency Virus Type 1 (HIV-1) Infection
TR-701 FA
Skin and Subcutaneous Tissue Bacterial Infections
Neostigmine
Anesthesia
5-Fluorouracil
Uterine Cervical Neoplasms
CB-183,315
Clostridium Difficile Infection
Pioglitazone
Type 2 Diabetes Mellitus
ceftriaxone sodium
Infection
PCV15
Pneumonia, Pneumococcal
eribulin
Metastatic Triple Negative Breast Cancer
Sitagliptin 50 mg
Type 2 Diabetes Mellitus
Preservative-Free Tafluprost or vehicle
Glaucoma
Preladenant 2 mg tablet
Parkinson Disease
Recombinant human luteinizing hormone (r-hLH)
Hypogonadism
Experimental: V503
Cervical Cancer
Peginterferon alfa-2b (PegIntron, SCH 54031)
Hepatitis D, Chronic
RNF
Multiple Sclerosis
H1 receptor antagonist
Ovarian Cancer
V501, Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine / Duration of Treatment: 4 years
Cervical Cancer
Telcagepant potassium 150 mg
Migraine
Hepatitis A Vaccine, Purified Inactivated (VAQTA™)
Hepatitis A Virus Infection
Vancomycin
Clostridium Difficile Infection
Sugammadex 0.5 mg/kg
Anesthesia
Ondansetron
Chemotherapy-Induced Nausea and Vomiting (CINV)
irinotecan
Esophageal Carcinoma
Dinaciclib
Chronic Lymphocytic Leukemia (CLL)
ATRIPLA™
Human Immunodeficiency Virus (HIV)
simvastatin 20 mg/ezetimibe
Hyperlipidemia
Anagrelide
Essential Thrombocythemia
ULO
Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Telcagepant 140 mg
Migraines
Telcagepant 300 mg soft gel capsules
Migraine
Leucovorin
Gastric Cancer
Rotarix™
Pneumococcal Infections
MK-3415
Clostridium Difficile Infection
Rescue medications for sacituzumab tirumotecan
Bladder Cancer
Leucovorin/ levoleucovorin
Metastatic Colorectal Cancer
epinastine nasal spray, low concentration, low dose volume
Seasonal Allergic Rhinitis
Letermovir tablet
Cytomegalovirus Infection
peginterferon alfa-2b (PEG2b) (SCH 54031)
Hepatitis C, Chronic
Prulifloxacin
Acute Gastroenteritis in Adult Travelers
Efalizumab
Moderate to Severe Psoriasis
Suvorexant High Dose (HD)
Primary Insomnia
FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan)
Epidermal Growth Factor Receptor (EGFR) Expressing Metastatic Colorectal Cancer
Sacituzumab Govitecan
Carcinoma, Non-Small-Cell Lung
Valganciclovir
CMV Disease
MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g)
Intra-abdominal Infection
Uridine 5'-Triphosphate (UTP) Solution for Inhalation
Lung Cancer
Glycopyrrolate
Surgical Procedures, Elective
Rotavirus Vaccine, Live, Oral, Pentavalent (V260, RotaTeq™)
Rotavirus
MK0524A, /Duration of Treatment : 4 Weeks
Flushing
Venetoclax
Leukemia, Lymphocytic, Chronic, B-Cell
Rebif® New Formulation (IFN-beta-1a, RNF)
Multiple Sclerosis, Relapsing-Remitting
Peginterferon alfa-2b (PEG)
Hepatitis C, Chronic
Ezetimibe
Hypercholesterolemia
Rocuronium bromide (Zemuron)
Anesthesia
Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine
Cervical Cancer
ART
HIV-1 Infection
Sitagliptin plus metformin
Type 2 Diabetes Mellitus
Linezolid
Pneumonia
liposomal doxorubicin
Breast Neoplasms
diquafosol tetrasodium (INS365) ophthalmic solution
Dry Eye Disease
REBETOL (ribavirin; SCH 18908)
Hepatitis C, Chronic
AzaSite
Bacterial Conjunctivitis
rosiglitazone
Type 2 Diabetes Mellitus
VARIVAX™ New Seed Process
Varicella
levoleucovorin
Esophageal Squamous Cell Carcinoma (ESCC)
V110
Pneumococcal Infection
Cetuximab plus Platinum-based Doublet Chemotherapy
Non-Small Cell Lung Cancer (NSCLC)
ribavirin (SCH 18908)
Hepatitis C, Chronic
MK-0524B
Primary Hypercholesterolemia
Cyclophosphamide
Diffuse Large B-Cell Lymphoma
L-PZQ ODT 50 mg/kg
Schistosomiasis
lovastatin
Atherosclerosis
MMRV (AMP)
Measles
Folinic Acid
Metastatic Colorectal Cancer
RotaTeq™ experimental formulation
Rotavirus Gastroenteritis
liraglutide
Diabetes Mellitus, Type 2
Ifinatamab Deruxtecan
Castration-Resistant Prostatic Cancer
Insulin Glargine
Type 2 Diabetes Mellitus
Bomedemstat
Thrombocythemia, Essential
Sulfonylurea
Type 2 Diabetes Mellitus
Pembrolizumab (MK-3475)
Merkel Cell Carcinoma
Hydroxyurea
Essential Thrombocythemia
Zidovudine
HIV Infections
Glimepiride
Type 2 Diabetes Mellitus
MK-0518
HIV Infections
Grazoprevir 100mg / Elbasvir 50 mg FDC
Chronic Hepatitis C Virus
Kuvan®
Phenylketonuria
Tulisokibart
Hidradenitis Suppurativa
Pioglitazone hydrochloride
Type 2 Diabetes Mellitus
BCG
Urinary Bladder Neoplasms
Rebif®
Clinically Isolated Syndrome
Glimepiride or gliclazide
Type 2 Diabetes Mellitus
Zoster Vaccine, Live, (Oka-Merck)
Varicella Virus Infection
Dapagliflozin
Type 2 Diabetes Mellitus
Grazoprevir 100 mg/Elbasvir 50 mg fixed-dose combination tablets
Chronic Hepatitis C
Zoster Vaccine, Live, (Oka-Merck), ZOSTAVAX™
Herpes Zoster
Sitagliptin 100 mg/simvastatin 40 mg FDC
Type 2 Diabetes Mellitus
Prevnar 13®
Streptococcus Pneumoniae Infection
Ertugliflozin 10 mg
Type 2 Diabetes Mellitus
MK0831
HIV Infections
Preservative-Free Tafluprost
Open-angle Glaucoma
Palivizumab
RSV Infection
Rotateq™
Rotavirus Infections
Clesrovimab
Respiratory Syncytial Viruses
ProQuad (Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live)
Measles
Filgrastim
Metastatic Non-small Cell Lung Cancer
granisetron
Chemotherapy-induced Nausea and Vomiting (CINV)
MK-8527
Human Immunodeficiency Virus (HIV)
PCV15 - Part B
Pneumococcal Disease
Zilovertamab vedotin
B-cell Acute Lymphoblastic Leukemia
Doravirine, Tenofovir, Lamivudine
HIV-1 Infection
Pembrolizumab/Quavonlimab
Colorectal Cancer
MK-5172A
Chronic Hepatitis C
PegIntron (peginterferon alfa-2b; SCH 54031)
Hepatitis
Grazoprevir
Chronic Hepatitis C (CHC)
PEG-Intron
Hepatitis C
Granulocyte Colony-Stimulating Factor (G-CSF)
DLBCL
Emtricitabine/tenofovir disoproxil (FTC/TDF)
Human Immunodeficiency Virus (HIV)
Zoster Vaccine, Live
Herpes Zoster
Efprezimod alfa
Graft Versus Host Disease
Zoster Vaccine, Live (AMP)
Herpes Zoster
Cisplatin/Carboplatin
Carcinoma, Squamous Cell of Head and Neck
ProQuad® manufactured with recombinant Human Albumin (rHA)
Measles
Gardasil™
Papillomavirus Infections
Varicella Virus Vaccine Live (Oka-Merck)
Varicella
Fosaprepitant dimeglumine
Chemotherapy-Induced Nausea and Vomiting (CINV)
V181
Healthy
Aprepitant 125 mg
Chemotherapy Induced Nausea and Vomiting
Human Papillomavirus (HPV) 16 Monovalent
Cervical Cancer
PegIntron
Hepatitis C
Atropine
Anesthesia, General
Glycemic Rescue 1
Diabetes Mellitus
Axitinib
Renal Cell Carcinoma
Sitagliptin 100 mg q.d.+ Pioglitazone 45 mg q.d.
Type 2 Diabetes Mellitus
Androgen Deprivation Therapy (ADT)
Metastatic Hormone-Sensitive Prostate Cancer
Dacarbazine
Classical Hodgkin Lymphoma
Cisplatin (as radiosensitizer)
Endometrial Neoplasms
Peginterferon alfa-2b (PEG2b)
Hepatitis C, Chronic
Peg-interferon alfa-2b
Hepatitis C, Chronic
peg-Interferon alfa-2a
Hepatitis C, Chronic
Calderasib
Non-small Cell Lung Cancer
ZOSTAVAX
Herpes Zoster
(Gardasil™) human papillomavirus (types 6, 11, 16, 18) recombinant vaccine
Condylomata Acuminata
Metronidazole
Complicated Intra-abdominal Infections
H2 Receptor Antagonist
Non-small Cell Lung Cancer (NSCLC)
RotaTeq®
Meningitis, Meningococcal
Boceprevir (BOC)
Chronic Hepatitis C
Intismeran autogene
Bladder Cancer
MK0869, aprepitant
Postoperative Nausea and Vomiting
Cabozantinib
Renal Cell Carcinoma (RCC)
Pembrolizumab/Vibostolimab Co-Formulation
Small Cell Lung Carcinoma
Voriconazole
Aspergillosis
Short ragweed pollen allergen extract
Rhinitis, Allergic, Seasonal
MK0803, lovastatin
Hypercholesterolemia
MK-3475A
Non-small Cell Lung Cancer
Trifluridine-Tipiracil
Gastroesophageal Cancer
Rescue medication
Non-Muscle Invasive Bladder Cancer
Tisotumab Vedotin
Cervical Cancer
Pembrolizumab (K)
Breast Cancer
niacin (+) laropiprant
Hypercholesterolemia
TAS-102 (trifluridine and tipiracil)
Colorectal Neoplasms
Diquafosol tetrasodium ophthalmic solution, 2%
Dry Eye Disease
favezelimab/pembrolizumab
Hodgkin Lymphoma
Golimumab
Spondylitis, Ankylosing
zoster vaccine live (ZOSTAVAX™)
Herpes Zoster
TAS-102
Colorectal Cancer
Infliximab + methotrexate (MTX)
Arthritis, Rheumatoid
Atorvastatin
Mixed Hyperlipidemia
Pergoveris®
Infertility
Meropenem
Healthcare-Associated Pneumonia
Gefapixant 15 mg BID
Chronic Cough
Standard of Care (SOC)
Solid Tumors
Enalapril
Hypertension
Tedizolid phosphate
Acute Bacterial Skin and Skin Structure Infections
r-hCG
Infertility
Ceftolozane/Tazobactam
Complicated Intra-Abdominal Infection
SC golimumab
Arthritis, Rheumatoid
Sitagliptin 100 mg
Type 2 Diabetes Mellitus
Voglibose
Diabetes Mellitus, Non-Insulin-Dependent
ER-niacin
Primary Hypercholesterolaemia
MK-1293
Type 1 Diabetes Mellitus
CXA-201 and metronidazole
Complicated Intra-abdominal Infection
Bisoprolol/Amlodipine (Bisoprolol failed group)
Hypertension
PAR-101/OPT-80
Clostridium Infections
Everolimus
Metastatic Breast Cancer
ZOSTAVAX™
Herpes Zoster
cetuximab + cisplatin + vinorelbine
Non Small Cell Lung Cancer (NSCLC)
sitagliptin 100 mg q.d./metformin ≥ 1500 mg/day
Type 2 Diabetes Mellitus (T2DM)
Ribavirin (RBV)
Hepatitis C, Chronic
ER niacin (+) laropiprant (ERN/LRPT)
Dyslipidemia
Vancomycin (or equivalent)
Acute Hematogenous Osteomyelitis
Palbociclib
Renal Cell Carcinoma
MK0966; Rofecoxib / Duration of Treatment: 156 weeks
Colorectal Adenoma
Elbasvir
Hepatitis C
V260
Rotavirus Gastroenteritis
Vericiguat tablet
Heart Failure
Pegylated interferon alfa-2b (SCH 54031)
Hepatitis C, Chronic
MK-8591A
HIV-1 Infection
Prevenar 13™
Pneumococcal Infections
Imipenem
Bacterial Pneumonia
RotaTeq™ - Rotavirus Vaccine, Live, Oral, Pentavalent
Vomiting
Zanzalintinib
Renal Cell Carcinoma
methotrexate
Psoriasis
5-FU
Metastatic Esophageal Squamous Cell Carcinoma
Vorinostat
Mesothelioma
Oxaliplatin
Colorectal Neoplasms
rolofylline
Heart Failure, Congestive
Patritumab Deruxtecan
Malignant Neoplasm
Gardasil
Papillomavirus Infections
Cetrorelix acetate
Polycystic Ovarian Syndrome
MK0966 / Duration of Treatment: 1 Days
Pain, Postoperative Arthroscopy
RotaTeq (V260)
Prevention of Rotavirus Gastroenteritis in Infants and Children Caused by Serotypes G1, G2, G3, G4, and G9
Aprepitant
Post-operative Nausea
Frespaciguat
Pulmonary Hypertension
Pembrolizumab/Vibostolimab
Lung Neoplasms
caspofungin acetate
Fungal Infection
MK0826, ertapenem sodium
Infections
Pembrolizumab (+) Berahyaluronidase alfa
Lung Cancer
Paclitaxel
Metastatic Non-Small Cell Lung Cancer
MK-6072
Clostridium Difficile Infection
Gliclazide
Type 2 Diabetes Mellitus
MK-0524A
Hypercholesteremia
Supportive care measures
Non-small Cell Lung Cancer (NSCLC)
ZOSTAVAX™ (concomitant)
Herpes Zoster
Doxorubicin
Breast Neoplasms
MK0974 50 mg
Migraine
Vitamin D3
Osteoporosis
MK0869, aprepitant / Duration of Treatment: 3 days
Nausea
neostigmine and glycopyrrolate or atropine
Neuromuscular Blockade
INS365 Ophthalmic Solution
Keratoconjunctivitis Sicca
Glipizide
Diabetes Mellitus, Type 2
Dexamethasone
Metastatic Castration-resistant Prostate Cancer (mCRPC)
M-M-R™II manufactured with recombinant Human Albumin (rHA) and VARIVAX®
Measles
regorafenib
Colorectal Cancer
sitagliptin phosphate (+) metformin hydrochloride
Type 2 Diabetes Mellitus
V110, pneumococcal vaccine polyvalent
Healthy
Sofosbuvir
Hepatitis C
Reformulated Raltegravir
HIV Infection
Background PAH Therapy
Pulmonary Arterial Hypertension
boceprevir (SCH 503034)
Chronic Hepatitis C
BIC/FTC/TAF
HIV-1 Infection
MK0991, caspofungin acetate / Duration of Treatment:
Fungal Infection
daptomycin
Pneumonia, Bacterial
Ertugliflozin 5 mg
Type 2 Diabetes Mellitus
Carboplatin
Carcinoma, Squamous Cell, Non-small-cell Lung
alvimopan
Ileus
pembrolizumab
Non-small Cell Lung Cancer
Nemtabrutinib
Chronic Lymphocytic Leukemia
Prevnar 13™
Pneumococcal Infections
Zoster Vaccine, Live (Zostavax™)
Shingles
DOR/ISL
HIV Infection
Rocuronium bromide (Org 9426)
Muscle Relaxation
Rocuronium 0.6 mg/kg intubating dose
Anesthesia
Rocuronium bolus maintenance
Anesthesia
V114
Pneumococcal Infections
sitagliptin phosphate
Type 2 Diabetes
Infliximab
Psoriasis
Ertugliflozin 15 mg
Type 2 Diabetes Mellitus
Metformin IR
Type 2 Diabetes Mellitus
Zoster Vaccine Live
Herpes Zoster
ER niacin/laropiprant
Diabetes Mellitus Type 2
Grazoprevir + Elbasvir
Hepatitis C Infection
Cetuximab + concomitant boost radiotherapy
Squamous Cell Carcinoma of the Head and Neck
L50/H12.5/A5
Hypertension
MK0826, /Duration of Treatment : 8 Weeks
Complicated Intra-Abdominal Infections
bortezomib
Multiple Myeloma
sugammadex
Neuromuscular Blockade
Tedizolid Phophate
Skin Diseases, Infectious
MK0507A, dorzolamide hydrochloride (+) timolol maleate
Glaucoma
MK0217A, alendronate sodium (+) cholecalciferol / Duration of Treatment: 24 weeks
Osteoporosis
raltegravir potassium
HIV Infections
rotavirus vaccine, live, oral, pentavalent
Rotavirus Infections
Grazoprevir/Elbasvir
Hepatitis C
Temozolomide
Glioblastoma
Cisplatin
Gastric Neoplasms
laropiprant/niacin (MK0524A)
Hypercholesterolemia
Sitagliptin
Type 2 Diabetes Mellitus
9vHPV vaccine
Papillomavirus Infections
Gonal-f®
Assisted Reproductive Techniques
Ibrutinib
Chronic Lymphocytic Leukemia
COL-1620
Luteal Hormone Supplementation in In-vitro Fertilization
V441, diptheria, tetanus, acellular pertussis, inactivated poliomyelitis, hepatitis B (recombinant), & Haemophilus influenza type b conjugate vaccine
Diphtheria
V501
Human
losartan potassium (+) hydrochlorothiazide
Hypertension
Preladenant
Parkinson Disease
Opevesostat
Prostate Cancer Metastatic
Sotatercept
Pulmonary Arterial Hypertension
Bezlotoxumab
Clostridium Difficile Infection
PCV20
Pneumococcal Infection
Ertugliflozin
Type 2 Diabetes Mellitus
Peginterferon alfa-2b
Carcinoma, Hepatocellular
Ipragliflozin
Type 2 Diabetes Mellitus
Rocuronium bromide
Anesthesia
Pemetrexed
Carcinoma, Nonsquamous Non-small-cell Lung
IMI/REL
Suspected or Documented Gram-negative Bacterial Infection
MK0966, rofecoxib
Postoperative Pain
Posaconazole oral suspension
Mycoses
Follitropin alfa liquid formulation
Infertility
Micronised Progesterone
Infertility
Imipenem+Cilastatin/Relebactam
Complicated Intra-abdominal Infection
Doravirine
HIV-1
Telcagepant
Migraine
Lenvatinib
Non-small Cell Lung Cancer
V503 (9-valent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] vaccine)
Human Papillomavirus Infection
V116
Pneumococcal Infection
Omarigliptin
Type 2 Diabetes Mellitus
MR Prednisone
Rheumatoid Arthritis
Pembrolizumab 200 mg
Non-Small-Cell Lung Carcinoma
Enfortumab vedotin (EV)
Bladder Cancer
Cetuximab
Gastric Cancer
Combination of (a) pegylated interferon alfa-2b and (b) rebetol
Liver Transplantation
Gefapixant 45 mg twice daily (BID)
Chronic Cough
Gefapixant
Chronic Cough
Indinavir sulfate
HIV Infections
Ridaforolimus
Sarcoma
V503
Papillomavirus Infections
Saizen®
Fibromyalgia
Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live
Measles
mFOLFOX6
Colorectal Carcinoma
Sitagliptin (MK0431)
Diabetes Mellitus, Type II
Cisplatin 100 mg/m^2
Head and Neck Neoplasms
Efavirenz
HIV Infections
Enlicitide Decanoate
Hypercholesterolemia
Odanacatib
Osteoporosis Postmenopausal
pegylated interferon alpha-2b
Hepatitis B, Chronic
V419
Bacterial Infections
Suvorexant
Insomnia
Rocuronium
Anesthesia, General
Gemcitabine
Biliary Tract Carcinoma
vaniprevir
Hepatitis C, Chronic
VARIVAX® PE34 Process
Varicella
Belzutifan
Renal Cell Carcinoma
Vorapaxar 2.5 mg
Cerebral Infarction
Rocurium
Anesthesia, General
Capecitabine
Advanced/Metastatic Gastroesophageal Adenocarcinoma
100 mg clindamycin /800 mg ketoconazole vaginal ovule
Vaginosis, Bacterial
QIV
Pneumonia, Pneumococcal
Acetaminophen/Paracetamol
Migraine Disorders
Ipilimumab
Melanoma
Alviompan
Bowel Dysfunction
taranabant
Smoking
Nab-paclitaxel
Non-small Cell Lung Cancer
V221, measles, mumps, rubella and varicella (Oka/Merck) virus vaccine live / Duration of Treatment: 12 weeks
Measles
V501, Gardasil, Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine / Duration of Treatment : 4 Years
Cervical Cancer
Enfortumab Vedotin
Urinary Bladder Cancer, Muscle-invasive
Cladribine Low Dose
Generalized Myasthenia Gravis
Metformin
Diabetes Mellitus
Colistimethate sodium (CMS)
Bacterial Infections
Acarbose
Type 2 Diabetes Mellitus
Fluorouracil (5-FU)
Urinary Bladder Neoplasms
Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
HPV Infections
2XP HEPTAVAX™-II SC
Hepatitis B
Abiraterone acetate
Prostatic Neoplasms
DOR
HIV-1 Infection
denufosol tetrasodium (INS37217) Inhalation Solution
Cystic Fibrosis
succinylcholine
Neuromuscular Blockade
MK-1084
Colon Adenocarcinoma
peg-IFN
Hepatitis C, Chronic
V503 Vaccine
Papillomavirus Infections
Saizen® A
Children Born With Serious Intra-uterine Growth Retardation
vinflunine
Urothelial Cancer
Modified Process Hepatitis B Vaccine
Hepatitis B
MK0557
Obesity
Pembrolizumab Formulated with Berahyaluronidase Alfa
Metastatic Non-small Cell Lung Cancer
Pneumovax™ 23
Pneumococcal Infections
Posaconazole
Mycoses
Metformin - Rescue
Diabetes Mellitus, Type 2
Infanrix® hexa
Varicella
IV Tulisokibart
Crohn's Disease
Daptomycin 4 mg/kg
Staphylococcal Infection
Gonalef® (Follitropin alfa)
Infertility
Fluconazole
Leukopenia
MK0826, ertapenem sodium / Duration of Treatment - 24 weeks
Foot Infections in Diabetic Patients
Naproxen
Endometriosis-related Pain
fidaxomicin
Clostridium Difficile-Associated Diarrhea (CDAD)
losartan potassium
Hypertension
anacetrapib
Coronary Heart Disease (CHD)
Suvorexant Low Dose (LD)
Primary Insomnia
dorzolamide hydrochloride (+) timolol maleate
Glaucoma
rofecoxib
Prostate Cancer
ProQuad®
Measles
MK1903
Dyslipidemia
Single low dose cyclophosphamide
Carcinoma, Non-Small-Cell Lung
denufosol tetrasodium Inhalation Solution
Cystic Fibrosis
CXA-101
Complicated Urinary Tract Infection
ATX-MS-1467
Multiple Sclerosis
MK-8189
Schizophrenia, Acute Episode
MK0524A, niacin (+) laropiprant / Duration of Treatment : 4 Weeks
Hypercholesterolemia
pegylated interferon
Chronic Hepatitis C
Pegylated Interferon (peg-IFN)
Hepatitis C
MK-1029 150 mg
Asthma
Multiple low dose cyclophosphamide
Multiple Myeloma
Islatravir
HIV-1 Infection
Recombinant human growth hormone (r-hGH)
Hypochondroplasia
Lonafarnib
Breast Cancer
tretinoin
Acute Myeloid Leukemia
denufosol tetrasodium (INS37217)
Cystic Fibrosis
OPT-80
Diarrhea
Dalantercept plus sorafenib
Advanced Adult Hepatocellular Carcinoma
Stavudine
HIV Infections
Ifinatamab Deruxtecan (I-DXd)
Small Cell Lung Cancer
Nelfinavir mesylate
HIV Infections
Dalotuzumab
Carcinoma, Non-small-cell Lung
MK-8777
Depression
Risperidone
Schizophrenia
ARQ 197
Pancreatic Neoplasms
Boserolimab
Small Cell Lung Cancer
r-hFSH
Infertility
2 NRTIs
Human Immunodeficiency Virus (HIV) Infection
ARQ 501
Cancer
Robatumumab
Colorectal Cancer
ADL5945 0.1 mg
Opioid Induced Constipation
MK0431, sitagliptin phosphate / Duration of Treatment: 21 Weeks
Diabetes Mellitus, Type II
PegIFN-2b
HIV Infections
M5717 330 mg
Acute Malaria
RSV A Memphis 37b
Respiratory Syncytial Virus
MK0826, ertapenem sodium /Duration of Treatment: 14 Days
Urinary Tract Infections
PegIntron (peginterferon alfa-2b)
Hepatitis C, Chronic
AR51 (12, 10)
Bacterial Infections; Virus Diseases
Relebactam 250 mg
Intra-abdominal Infections
Vibostolimab
Melanoma
MK0493
Obesity
MK0812 / Duration of Treatment: 12 Weeks
Arthritis, Rheumatoid
Atorvastatin/niacin extended-release
Carotid Atherosclerosis
EV
Bladder Cancer
Rebif
Multiple Sclerosis
INS37217 Nasal Spray
Perennial Allergic Rhinitis
MK0974
Migraine
MK0777
Generalized Anxiety Disorder
diphenhydramine
Carcinoma, Non-Small-Cell Lung
Ruzasvir
Hepatitis C
MK-0482
Carcinoma, Non-Small-Cell Lung
Uprifosbuvir
Hepatitis C
MK-8616
Neuromuscular Blockade
Benznidazole
Chagas Disease
Pneumococcal Conjugate Vaccine (V114)
Pneumococcal Infections
MK-0873
Rheumatoid Arthritis
Matuzumab
Esophageal Cancer
V114 Aluminum-adjuvanted
Pneumococcal Infections
Gefitinib
Non-small Cell Lung Carcinoma
Vibostolimab/Pembrolizumab
Carcinoma, Renal Cell
V504
Cervical Cancer
MK-3120
Urothelial Carcinoma
MK0431, sitagliptin phosphate / Duration of Treatment: 12 Weeks
Type 2 Diabetes Mellitus
Vicriviroc maleate
HIV
Navarixin
Solid Tumors
Daptomycin for Injection
Bacteremia
Exemestane
Breast Neoplasms
imipenem/cilastatin 500 mg
Urinary Tract Infections
UFOX + Cetuximab
Previously Untreated Metastatic Colorectal Cancer
SCH 619734
Cough
Ritonavir
HIV Infections
Ertugliflozin 25 mg
Diabetes Mellitus, Type 2
MK8141
Hypertension
cetuximab, cisplatin
Breast Neoplasm
Raludotatug Deruxtecan (R-DXd)
Gastrointestinal Cancer
Interferon beta-1a
Alzheimer's Disease
MK0639, indinavir sulfate / Duration of Treatment: 48 Weeks
HIV Infections
Tepotinib
Non-small Cell Lung Cancer
V114 Medium Dose
Pneumococcal Infections
V181 High-Potency Level
Dengue Disease
MK-3795
VHL Gene Mutation
ADL5747
Osteoarthritis of the Knee
Prednisolone
Lymphoma, Large B-Cell, Diffuse
cyclophosphamide (CPA)
Rectal Cancer
V114 Lot 1
Pneumococcal Infections
Biltricide (racemate praziquantel) oral tablets
Schistosomiasis
CXA-101/ tazobactam and metronidazole
Complicated Intra-abdominal Infection
TR-701 200 mg
Skin Diseases, Infectious
luspatercept
B-Thalassemia
Emfilermin, recombinant human leukemia inhibitory factor (r-hLIF)
Infertility Implantation Failure
SCH 900636
Depressive Disorders
MK-8690
Colitis Ulcerative
adavosertib
Ovarian Cancer
MK0822A
Vitamin D Deficiency
MK0633
Atherosclerosis
Pegylated Lyposomal Doxorubicin
Breast Neoplasm
MK0782
Stomach Ulcer
MK0249
Attention-Deficit/Hyperactivity Disorder (ADHD)
EMD 525797 250 mg
Metastatic Colorectal Cancer
Letermovir oral granules
Cytomegalovirus (CMV) Infection
Cilengitide 2000 mg once weekly
Squamous Cell Cancer
TR701 FA
Major Cutaneous Abscess
Doravirine, Tenofovir, Lamivudine - Blinded
HIV-1
MK-8435 (Org 25935) 4-8 mg
Schizophrenia
V940
Squamous Non-small Cell Lung Cancer
PR51 (3, 10)
Bacterial Infections; Virus Diseases
R-DXD
Lung Neoplasm
Efinopegdutide
Metabolic Dysfunction-Associated Steatotic Liver Disease
Raltegravir Film-coated Tablet
HIV Infection
MK-6096
Migraine
Pembrolizumab/vibostolimab coformulation
Bladder Cancer
Navarixin 10 mg
Psoriasis
PRA023 IV
Crohn Disease
irinotecan hydrochloride
Metastatic Colorectal Cancer
Efinopegdutide 20 mg/mL
Nonalcoholic Fatty Liver Disease
MK0736
Hypertension
MK-0941
Type 2 Diabetes Mellitus
Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 20/40/40/20
Papillomavirus Infections
Olaparib 400 mg
Metastatic Castration-Resistant Prostate Cancer
teicoplanin
Osteomyelitis
Miransertib
PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome (PS)
Ramucirumab
Gastroesophageal Junction
Vaniprevir 600 mg b.i.d.
Hepatitis C, Chronic
rolofyline
Congestive Heart Failure
MK0429
Post-Menopausal Osteoporosis
MK0686
Pain, Postoperative
MK-0893
Diabetes Mellitus, Type 2
IDX719
Hepatitis C, Chronic
Sitagliptin 25 mg
Glucose Intolerance
S-1
Gastric Cancer
ADL5859 30 mg
Acute Pain
SCH 900271 15mg
Primary Hypercholesterolemia
ZA
Breast Cancer
MK633
Chronic Obstructive Pulmonary Disease (COPD)
L-756423
HIV Infections
MK3207- 2.5 mg
Migraine
timolol/dorzolamide combination
Glaucoma
Doxorubicin hydrochloride
Breast Neoplasms
vinblastine
Hodgkin Lymphoma
Esmeron®
Neuromuscular Blockade
r-FSH
Ovarian Stimulation
MK5757
Schizophrenia
MK2295
Pain, Postoperative
Enclitide Chloride
Hypercholesterolemia
NM283 plus Peg-IFNα-2a
Chronic Hepatitis C
Gefapixant 50 mg
Asthma
MK-6213
Hypercholesterolemia
coformulation pembrolizumab/quavonlimab
Small Cell Lung Carcinoma
MK-2060
End-Stage Renal Disease
IDX184
Chronic Hepatitis C Infection
Pleconaril
Asthma
Gocatamig
Small-Cell Lung Cancer
Quavonlimab
Advanced Solid Tumors
ATRA
Melanoma
Samatasvir
Chronic Hepatitis C Virus
MK-1167
Alzheimer Disease
SCH 530348
Arterial Obstructive Diseases
MK-1200
Advanced Solid Tumors
MK-2214
Early Alzheimer's Disease
Epinastine Nasal Spray
Seasonal Allergic Rhinitis
Posaconazole IV
Invasive Aspergillosis
Grazoprevir (GZR)
Hepatitis C Virus
SCH 727965
Breast Neoplasms
V114-A
Pneumococcal Infections
IFN beta 1a 44 mcg TIW
Multiple Sclerosis
Pegylated Liposomal Doxorubicin
Breast Neoplasm
Avelumab
Squamous Non-Small Cell Lung Cancer
MK-4830
Carcinoma, Non-Small-Cell Lung
Dabrafenib
Melanoma
Ulevostinag
Head and Neck Squamous Cell Carcinoma (HNSCC)
Tepotinib 300 mg
Carcinoma, Hepatocellular
I-DXd
Esophageal Squamous Cell Carcinoma
zoster vaccine live (Oka/Merck)
Shingles
Avastin
High-grade Serous Ovarian Carcinoma
Raludotatug Deruxtecan
Ovarian Cancer Recurrent
MK0524A, niacin (+) laropiprant / Duration of Treatment: 17 Weeks
Flushing
Atacicept
Rheumatoid Arthritis
VigantOL oil plus interferon beta-1a (Rebif)
Relapsing-Remitting Multiple Sclerosis
Coformulation favezelimab/pembrolizumab
Esophageal Squamous Cell Carcinoma (ESCC)
Vibegron
Urinary Bladder, Overactive
ridaforolimus (MK8669)
Prostate Cancer
SCH 56592
Onychomycosis
Org 34517
Depression
MK-1029
Asthma
MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment 6 Months
B-cell Lymphoma
Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate
HIV-1 Infection
ARQ 501 in combination with gemcitabine
Pancreatic Cancer
Coformulated favezelimab/pembrolizumab
Metastatic Urothelial Carcinoma
Fosaprepitant
Chemotherapy-induced Nausea and Vomiting
MK0524A, /Duration of Treatment : 8 Weeks
Flushing
Rolapitant Dose 1
Postoperative Nausea and Vomiting
val-mCyd
Chronic Hepatitis C
V205C, measles, mumps, and rubella virus vaccine live
Measles
MK0359
Pulmonary Disease, Chronic Obstructive
Gefapixant 45 mg
Chronic Cough
Farnesyl Protein Transferase Inhibitor
Leukemia
Grazoprevir/Elbasvir FDC
Hepatitis C
ADL5859
Peripheral Neuropathy
MK2461
Neoplasm
MK-5442
Osteoporosis
Donepezil
Alzheimer's Disease
MK0524
Seasonal Allergies
MK-0634 50 mg
Urinary Incontinence
MK0991, caspofungin acetate
Aspergillosis
SCH 486757
Cough
Tecemotide (L-BLP25)
Lung Neoplasms
measles, mumps, and rubella virus vaccine live
Measles
peginterferon alfa 2b
Hepatitis C, Chronic
Gefapixant 100 mg
Refractory Chronic Cough
TS-1
Gastric Cancer
Vecuronium
Anesthesia, General
medroxyprogesterone acetate tablets OR megestrol acetate
Endometrial Cancer
AS900672-Enriched 50 microgram (mcg)
Infertility
Vicriviroc 30 mg
HIV Infections
valopicitabine
Chronic Hepatitis C
MK0677
Alzheimer's Disease
Cilengitide
Carcinoma, Non-Small-Cell Lung
Rescue
Type II Diabetes Mellitus
ridaforolimus + dalotuzumab
Breast Cancer
ARQ 197 plus erlotinib
Metastatic Non-Small Cell Lung Cancer
ecallantide
Bloodloss
Recombinant human follicle stimulating hormone (r-hFSH)
Infertility
MK0991, caspofungin acetate/Duration of Treatment: variable
Candidiasis
Posaconazole IV 6 mg/kg
Invasive Fungal Infection
ibuprofen
Migraine
Pembrolizumab (neoadjuvant)
Lung Neoplasm Malignant
MK0518
HIV Infections
ADL5945 0.25 mg
Constipation
TRUVADA®
HIV Infections
M5717 60 mg
Malaria Infection
Antihistamine
Esophageal Squamous Cell Carcinoma
MK-5684
Malignant Neoplasm
FOLFIRI
Metastatic Colorectal Cancer
Ertugliflozin 1 mg
Diabetes Mellitus, Type 2
Oral testosterone undecanoate (Andriol)
Hypogonadism
M5049 low dose
Systemic Lupus Erythematosus
Azithromycin ophthalmic solution, 1%
Blepharitis
Vorapaxar
Atherosclerosis
Docetetaxel
Carcinoma, Non-Small-Cell Lung
Itraconazole
Chronic Hepatitis C
Pegylated Interferon Alfa
Chronic Hepatitis C
KW-3902IV
Heart Failure, Congestive
Favezelimab
Advanced Non-Small Cell Lung Cancer
tildrakizumab
Psoriasis
SCH 900538
Seasonal Allergic Rhinitis
SCH 497079
Obesity
EBR/GZR FDC Tablet
HCV Infection
Pertuzumab
Breast Neoplasms
epinastine 0.1%
Allergic Rhinitis
MK0916
Diabetes Mellitus, Type 2
V160
Cytomegalovirus (CMV) Infections
MK-2140 (zilovertamab vedotin)
Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (V501)
HPV Infections
MK-8998
Schizophrenia
Cabazitaxel
Prostatic Neoplasms, Castration-Resistant
L-dopa
Parkinson Disease
MK0364
Obesity
Sacituzumab Tirumotecan (sac-TMT)
Gastroesophageal Junction
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Lamivudine | Phase 3 | HIV Infections | - | - |
RotaTeq™, rotavirus vaccine, live, oral, pentavalent | Phase 3 | Rotavirus Infections | - | - |
Quadrivalent Human Papillomavirus (HPV, Types 6, 11, 16, 18) Recombinant Vaccine (Gardasil®) | Phase 3 | Papillomavirus Infections | - | - |
Infliximab + methotrexate (IFX + MTX) | Phase 3 | Arthritis, Psoriatic | - | - |
Rebif New Formulation + prophylactic Ibuprofen | Phase 3 | Relapsing Multiple Sclerosis | - | - |
PPSV23 | Phase 3 | Pneumococcal Disease | - | - |
Boceprevir | Phase 3 | Chronic Hepatitis C Genotype 1 | - | - |
Esmirtazapine | Phase 3 | Insomnia | - | - |
hydrochlorothiazide (HCTZ) | Phase 3 | Hypertension | - | - |
PNEUMOVAX™23 | Phase 3 | Pneumococcal Infections | - | - |
Cetuximab + Platinum (Cisplatin or Carboplatin) + 5Fluorouracil (5-FU) | Phase 3 | Head and Neck Cancer | - | - |
Ertapenem sodium | Phase 3 | Infection; Diabetic Foot | - | - |
MK0826, ertapenem sodium / Duration of Treatment: 14 Days | Phase 3 | Infection | - | - |
Prednisone | Phase 3 | Prostatic Neoplasms | - | - |
pneumococcal 23v polysaccharide vaccine | Phase 3 | Pneumococcal Infection | - | - |
niacin (+) laropiprant (+) simvastatin | Phase 3 | Primary Hypercholesterolemia | - | - |
Modified Process Hepatitis B Vaccine (Experimental) | Phase 3 | Hepatitis B | - | - |
Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL™) | Phase 3 | Papillomavirus Infections | - | - |
V212 | Phase 3 | Herpes Zoster | - | - |
Dexamethasone 4 mg | Phase 3 | Non-Small-Cell Lung Carcinoma | - | - |
Combination of pegylated interferon alfa-2b (PEG-Intron®) and ribavirin (Rebetol®) | Phase 3 | Hepatitis C, Chronic | - | - |
Open-label Metformin | Phase 3 | Type 2 Diabetes | - | - |
Olaparib | Phase 3 | Ovarian Cancer | - | - |
Lantus™ | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Raptiva | Phase 3 | Moderate to Severe Psoriasis | - | - |
Pembrolizumab 400 mg | Phase 3 | Small Cell Lung Cancer | - | - |
mRNA-1273 Vaccine | Phase 3 | Papillomavirus Infections | - | - |
docetaxel | Phase 3 | Endometrial Neoplasms | - | - |
Rescue Medications | Phase 3 | Cervical Cancer | - | - |
MTX | Phase 3 | Arthritis, Rheumatoid | - | - |
V501, Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine | Phase 3 | Cervical Cancer | - | - |
V920 Consistency Lot A | Phase 3 | Prevention of Ebola Infection | - | - |
Peginterferon alfa-2a | Phase 3 | Hepatitis C, Chronic | - | - |
Letermovir | Phase 3 | Cytomegalovirus Infection | - | - |
Sacituzumab tirumotecan | Phase 3 | Colorectal Cancer | - | - |
V232 Modified Process Hepatitis B Vaccine: Lot A | Phase 3 | Hepatitis B Infection | - | - |
PCV13 | Phase 3 | Pneumococcal Infections | - | - |
Varicella Virus Vaccine Live (2007 Process) (Oka/Merck) | Phase 3 | Varicella | - | - |
Ribavirin | Phase 3 | Hepatitis C | - | - |
Anacetrapib 100 mg | Phase 3 | Hypercholesterolemia | - | - |
Tobramycin | Phase 3 | Bacterial Conjunctivitis | - | - |
Pegylated interferon alfa-2b | Phase 3 | Hepatitis C | - | - |
Basal Insulin | Phase 3 | Type 2 Diabetes Mellitus | - | - |
0.9% sodium chloride (NaCl) | Phase 3 | Anesthesia | - | - |
sac-TMT | Phase 3 | Non-small Cell Lung Cancer | - | - |
Grazoprevir 100 mg/Elbasvir 50 mg FDC tablet (MK-5172A) | Phase 3 | Chronic Hepatitis C | - | - |
Org 50081 | Phase 3 | Insomnia | - | - |
HBVAXPRO™ | Phase 3 | Hepatitis B | - | - |
VARIVAX™ | Phase 3 | Varicella | - | - |
SC Tulisokibart | Phase 3 | Ulcerative Colitis | - | - |
Insulin | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Vericiguat | Phase 3 | Heart Failure | - | - |
DAPTACEL™ | Phase 3 | Bacterial Infections | - | - |
etoposide | Phase 3 | Carcinoma, Non-Small-Cell Lung | - | - |
IMI/REL FDC | Phase 3 | Hospital-Acquired Bacterial Pneumonia | - | - |
sitagliptin 100 mg q.d./pioglitazone 30 mg q.d | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Vicriviroc | Phase 3 | HIV Infections | - | - |
Molnupiravir | Phase 3 | Coronavirus Disease (COVID-19) | - | - |
losartan potassium + hydrochlorothiazide + amlodipine besylate (MK-0954E) | Phase 3 | Hypertension | - | - |
ertapenem sodium (MK0826) | Phase 3 | Urinary Tract Infection | - | - |
Pegylated liposomal doxorubicin (SCH 200746) | Phase 3 | Breast Cancer | - | - |
Enzalutamide | Phase 3 | Metastatic Hormone-Sensitive Prostate Cancer | - | - |
peginterferon alfa-2b (SCH 54031) | Phase 3 | Chronic Hepatitis C | - | - |
Induction dose of (a) infliximab followed by combination of (b) pegylated interferon alfa-2b and (c) ribavirin | Phase 3 | Hepatitis C, Chronic | - | - |
Pembrolizumab SC | Phase 3 | Non-Small Cell Lung Cancer | - | - |
ISL | Phase 3 | Human Immunodeficiency Virus Type 1 (HIV-1) Infection | - | - |
TR-701 FA | Phase 3 | Skin and Subcutaneous Tissue Bacterial Infections | - | - |
Neostigmine | Phase 3 | Anesthesia | - | - |
5-Fluorouracil | Phase 3 | Uterine Cervical Neoplasms | - | - |
CB-183,315 | Phase 3 | Clostridium Difficile Infection | - | - |
Pioglitazone | Phase 3 | Type 2 Diabetes Mellitus | - | - |
ceftriaxone sodium | Phase 3 | Infection | - | - |
PCV15 | Phase 3 | Pneumonia, Pneumococcal | - | - |
eribulin | Phase 3 | Metastatic Triple Negative Breast Cancer | - | - |
Sitagliptin 50 mg | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Preservative-Free Tafluprost or vehicle | Phase 3 | Glaucoma | - | - |
Preladenant 2 mg tablet | Phase 3 | Parkinson Disease | - | - |
Recombinant human luteinizing hormone (r-hLH) | Phase 3 | Hypogonadism | - | - |
Experimental: V503 | Phase 3 | Cervical Cancer | - | - |
Peginterferon alfa-2b (PegIntron, SCH 54031) | Phase 3 | Hepatitis D, Chronic | - | - |
RNF | Phase 3 | Multiple Sclerosis | - | - |
H1 receptor antagonist | Phase 3 | Ovarian Cancer | - | - |
V501, Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine / Duration of Treatment: 4 years | Phase 3 | Cervical Cancer | - | - |
Telcagepant potassium 150 mg | Phase 3 | Migraine | - | - |
Hepatitis A Vaccine, Purified Inactivated (VAQTA™) | Phase 3 | Hepatitis A Virus Infection | - | - |
Vancomycin | Phase 3 | Clostridium Difficile Infection | - | - |
Sugammadex 0.5 mg/kg | Phase 3 | Anesthesia | - | - |
Ondansetron | Phase 3 | Chemotherapy-Induced Nausea and Vomiting (CINV) | - | - |
irinotecan | Phase 3 | Esophageal Carcinoma | - | - |
Dinaciclib | Phase 3 | Chronic Lymphocytic Leukemia (CLL) | - | - |
ATRIPLA™ | Phase 3 | Human Immunodeficiency Virus (HIV) | - | - |
simvastatin 20 mg/ezetimibe | Phase 3 | Hyperlipidemia | - | - |
Anagrelide | Phase 3 | Essential Thrombocythemia | - | - |
ULO | Phase 3 | Human Immunodeficiency Virus Type 1 (HIV-1) Infection | - | - |
Telcagepant 140 mg | Phase 3 | Migraines | - | - |
Telcagepant 300 mg soft gel capsules | Phase 3 | Migraine | - | - |
Leucovorin | Phase 3 | Gastric Cancer | - | - |
Rotarix™ | Phase 3 | Pneumococcal Infections | - | - |
MK-3415 | Phase 3 | Clostridium Difficile Infection | - | - |
Rescue medications for sacituzumab tirumotecan | Phase 3 | Bladder Cancer | - | - |
Leucovorin/ levoleucovorin | Phase 3 | Metastatic Colorectal Cancer | - | - |
epinastine nasal spray, low concentration, low dose volume | Phase 3 | Seasonal Allergic Rhinitis | - | - |
Letermovir tablet | Phase 3 | Cytomegalovirus Infection | - | - |
peginterferon alfa-2b (PEG2b) (SCH 54031) | Phase 3 | Hepatitis C, Chronic | - | - |
Prulifloxacin | Phase 3 | Acute Gastroenteritis in Adult Travelers | - | - |
Efalizumab | Phase 3 | Moderate to Severe Psoriasis | - | - |
Suvorexant High Dose (HD) | Phase 3 | Primary Insomnia | - | - |
FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan) | Phase 3 | Epidermal Growth Factor Receptor (EGFR) Expressing Metastatic Colorectal Cancer | - | - |
Sacituzumab Govitecan | Phase 3 | Carcinoma, Non-Small-Cell Lung | - | - |
Valganciclovir | Phase 3 | CMV Disease | - | - |
MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g) | Phase 3 | Intra-abdominal Infection | - | - |
Uridine 5'-Triphosphate (UTP) Solution for Inhalation | Phase 3 | Lung Cancer | - | - |
Glycopyrrolate | Phase 3 | Surgical Procedures, Elective | - | - |
Rotavirus Vaccine, Live, Oral, Pentavalent (V260, RotaTeq™) | Phase 3 | Rotavirus | - | - |
MK0524A, /Duration of Treatment : 4 Weeks | Phase 3 | Flushing | - | - |
Venetoclax | Phase 3 | Leukemia, Lymphocytic, Chronic, B-Cell | - | - |
Rebif® New Formulation (IFN-beta-1a, RNF) | Phase 3 | Multiple Sclerosis, Relapsing-Remitting | - | - |
Peginterferon alfa-2b (PEG) | Phase 3 | Hepatitis C, Chronic | - | - |
Ezetimibe | Phase 3 | Hypercholesterolemia | - | - |
Rocuronium bromide (Zemuron) | Phase 3 | Anesthesia | - | - |
Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine | Phase 3 | Cervical Cancer | - | - |
ART | Phase 3 | HIV-1 Infection | - | - |
Sitagliptin plus metformin | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Linezolid | Phase 3 | Pneumonia | - | - |
liposomal doxorubicin | Phase 3 | Breast Neoplasms | - | - |
diquafosol tetrasodium (INS365) ophthalmic solution | Phase 3 | Dry Eye Disease | - | - |
REBETOL (ribavirin; SCH 18908) | Phase 3 | Hepatitis C, Chronic | - | - |
AzaSite | Phase 3 | Bacterial Conjunctivitis | - | - |
rosiglitazone | Phase 3 | Type 2 Diabetes Mellitus | - | - |
VARIVAX™ New Seed Process | Phase 3 | Varicella | - | - |
levoleucovorin | Phase 3 | Esophageal Squamous Cell Carcinoma (ESCC) | - | - |
V110 | Phase 3 | Pneumococcal Infection | - | - |
Cetuximab plus Platinum-based Doublet Chemotherapy | Phase 3 | Non-Small Cell Lung Cancer (NSCLC) | - | - |
ribavirin (SCH 18908) | Phase 3 | Hepatitis C, Chronic | - | - |
MK-0524B | Phase 3 | Primary Hypercholesterolemia | - | - |
Cyclophosphamide | Phase 3 | Diffuse Large B-Cell Lymphoma | - | - |
L-PZQ ODT 50 mg/kg | Phase 3 | Schistosomiasis | - | - |
lovastatin | Phase 3 | Atherosclerosis | - | - |
MMRV (AMP) | Phase 3 | Measles | - | - |
Folinic Acid | Phase 3 | Metastatic Colorectal Cancer | - | - |
RotaTeq™ experimental formulation | Phase 3 | Rotavirus Gastroenteritis | - | - |
liraglutide | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
Ifinatamab Deruxtecan | Phase 3 | Castration-Resistant Prostatic Cancer | - | - |
Insulin Glargine | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Bomedemstat | Phase 3 | Thrombocythemia, Essential | - | - |
Sulfonylurea | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Pembrolizumab (MK-3475) | Phase 3 | Merkel Cell Carcinoma | - | - |
Hydroxyurea | Phase 3 | Essential Thrombocythemia | - | - |
Zidovudine | Phase 3 | HIV Infections | - | - |
Glimepiride | Phase 3 | Type 2 Diabetes Mellitus | - | - |
MK-0518 | Phase 3 | HIV Infections | - | - |
Grazoprevir 100mg / Elbasvir 50 mg FDC | Phase 3 | Chronic Hepatitis C Virus | - | - |
Kuvan® | Phase 3 | Phenylketonuria | - | - |
Tulisokibart | Phase 3 | Hidradenitis Suppurativa | - | - |
Pioglitazone hydrochloride | Phase 3 | Type 2 Diabetes Mellitus | - | - |
BCG | Phase 3 | Urinary Bladder Neoplasms | - | - |
Rebif® | Phase 3 | Clinically Isolated Syndrome | - | - |
Glimepiride or gliclazide | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Zoster Vaccine, Live, (Oka-Merck) | Phase 3 | Varicella Virus Infection | - | - |
Dapagliflozin | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Grazoprevir 100 mg/Elbasvir 50 mg fixed-dose combination tablets | Phase 3 | Chronic Hepatitis C | - | - |
Zoster Vaccine, Live, (Oka-Merck), ZOSTAVAX™ | Phase 3 | Herpes Zoster | - | - |
Sitagliptin 100 mg/simvastatin 40 mg FDC | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Prevnar 13® | Phase 3 | Streptococcus Pneumoniae Infection | - | - |
Ertugliflozin 10 mg | Phase 3 | Type 2 Diabetes Mellitus | - | - |
MK0831 | Phase 3 | HIV Infections | - | - |
Preservative-Free Tafluprost | Phase 3 | Open-angle Glaucoma | - | - |
Palivizumab | Phase 3 | RSV Infection | - | - |
Rotateq™ | Phase 3 | Rotavirus Infections | - | - |
Clesrovimab | Phase 3 | Respiratory Syncytial Viruses | - | - |
ProQuad (Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live) | Phase 3 | Measles | - | - |
Filgrastim | Phase 3 | Metastatic Non-small Cell Lung Cancer | - | - |
granisetron | Phase 3 | Chemotherapy-induced Nausea and Vomiting (CINV) | - | - |
MK-8527 | Phase 3 | Human Immunodeficiency Virus (HIV) | - | - |
PCV15 - Part B | Phase 3 | Pneumococcal Disease | - | - |
Zilovertamab vedotin | Phase 3 | B-cell Acute Lymphoblastic Leukemia | - | - |
Doravirine, Tenofovir, Lamivudine | Phase 3 | HIV-1 Infection | - | - |
Pembrolizumab/Quavonlimab | Phase 3 | Colorectal Cancer | - | - |
MK-5172A | Phase 3 | Chronic Hepatitis C | - | - |
PegIntron (peginterferon alfa-2b; SCH 54031) | Phase 3 | Hepatitis | - | - |
Grazoprevir | Phase 3 | Chronic Hepatitis C (CHC) | - | - |
PEG-Intron | Phase 3 | Hepatitis C | - | - |
Granulocyte Colony-Stimulating Factor (G-CSF) | Phase 3 | DLBCL | - | - |
Emtricitabine/tenofovir disoproxil (FTC/TDF) | Phase 3 | Human Immunodeficiency Virus (HIV) | - | - |
Zoster Vaccine, Live | Phase 3 | Herpes Zoster | - | - |
Efprezimod alfa | Phase 3 | Graft Versus Host Disease | - | - |
Zoster Vaccine, Live (AMP) | Phase 3 | Herpes Zoster | - | - |
Cisplatin/Carboplatin | Phase 3 | Carcinoma, Squamous Cell of Head and Neck | - | - |
ProQuad® manufactured with recombinant Human Albumin (rHA) | Phase 3 | Measles | - | - |
Gardasil™ | Phase 3 | Papillomavirus Infections | - | - |
Varicella Virus Vaccine Live (Oka-Merck) | Phase 3 | Varicella | - | - |
Fosaprepitant dimeglumine | Phase 3 | Chemotherapy-Induced Nausea and Vomiting (CINV) | - | - |
V181 | Phase 3 | Healthy | - | - |
Aprepitant 125 mg | Phase 3 | Chemotherapy Induced Nausea and Vomiting | - | - |
Human Papillomavirus (HPV) 16 Monovalent | Phase 3 | Cervical Cancer | - | - |
PegIntron | Phase 3 | Hepatitis C | - | - |
Atropine | Phase 3 | Anesthesia, General | - | - |
Glycemic Rescue 1 | Phase 3 | Diabetes Mellitus | - | - |
Axitinib | Phase 3 | Renal Cell Carcinoma | - | - |
Sitagliptin 100 mg q.d.+ Pioglitazone 45 mg q.d. | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Androgen Deprivation Therapy (ADT) | Phase 3 | Metastatic Hormone-Sensitive Prostate Cancer | - | - |
Dacarbazine | Phase 3 | Classical Hodgkin Lymphoma | - | - |
Cisplatin (as radiosensitizer) | Phase 3 | Endometrial Neoplasms | - | - |
Peginterferon alfa-2b (PEG2b) | Phase 3 | Hepatitis C, Chronic | - | - |
Peg-interferon alfa-2b | Phase 3 | Hepatitis C, Chronic | - | - |
peg-Interferon alfa-2a | Phase 3 | Hepatitis C, Chronic | - | - |
Calderasib | Phase 3 | Non-small Cell Lung Cancer | - | - |
ZOSTAVAX | Phase 3 | Herpes Zoster | - | - |
(Gardasil™) human papillomavirus (types 6, 11, 16, 18) recombinant vaccine | Phase 3 | Condylomata Acuminata | - | - |
Metronidazole | Phase 3 | Complicated Intra-abdominal Infections | - | - |
H2 Receptor Antagonist | Phase 3 | Non-small Cell Lung Cancer (NSCLC) | - | - |
RotaTeq® | Phase 3 | Meningitis, Meningococcal | - | - |
Boceprevir (BOC) | Phase 3 | Chronic Hepatitis C | - | - |
Intismeran autogene | Phase 3 | Bladder Cancer | - | - |
MK0869, aprepitant | Phase 3 | Postoperative Nausea and Vomiting | - | - |
Cabozantinib | Phase 3 | Renal Cell Carcinoma (RCC) | - | - |
Pembrolizumab/Vibostolimab Co-Formulation | Phase 3 | Small Cell Lung Carcinoma | - | - |
Voriconazole | Phase 3 | Aspergillosis | - | - |
Short ragweed pollen allergen extract | Phase 3 | Rhinitis, Allergic, Seasonal | - | - |
MK0803, lovastatin | Phase 3 | Hypercholesterolemia | - | - |
MK-3475A | Phase 3 | Non-small Cell Lung Cancer | - | - |
Trifluridine-Tipiracil | Phase 3 | Gastroesophageal Cancer | - | - |
Rescue medication | Phase 3 | Non-Muscle Invasive Bladder Cancer | - | - |
Tisotumab Vedotin | Phase 3 | Cervical Cancer | - | - |
Pembrolizumab (K) | Phase 3 | Breast Cancer | - | - |
niacin (+) laropiprant | Phase 3 | Hypercholesterolemia | - | - |
TAS-102 (trifluridine and tipiracil) | Phase 3 | Colorectal Neoplasms | - | - |
Diquafosol tetrasodium ophthalmic solution, 2% | Phase 3 | Dry Eye Disease | - | - |
favezelimab/pembrolizumab | Phase 3 | Hodgkin Lymphoma | - | - |
Golimumab | Phase 3 | Spondylitis, Ankylosing | - | - |
zoster vaccine live (ZOSTAVAX™) | Phase 3 | Herpes Zoster | - | - |
TAS-102 | Phase 3 | Colorectal Cancer | - | - |
Infliximab + methotrexate (MTX) | Phase 3 | Arthritis, Rheumatoid | - | - |
Atorvastatin | Phase 3 | Mixed Hyperlipidemia | - | - |
Pergoveris® | Phase 3 | Infertility | - | - |
Meropenem | Phase 3 | Healthcare-Associated Pneumonia | - | - |
Gefapixant 15 mg BID | Phase 3 | Chronic Cough | - | - |
Standard of Care (SOC) | Phase 3 | Solid Tumors | - | - |
Enalapril | Phase 3 | Hypertension | - | - |
Tedizolid phosphate | Phase 3 | Acute Bacterial Skin and Skin Structure Infections | - | - |
r-hCG | Phase 3 | Infertility | - | - |
Ceftolozane/Tazobactam | Phase 3 | Complicated Intra-Abdominal Infection | - | - |
SC golimumab | Phase 3 | Arthritis, Rheumatoid | - | - |
Sitagliptin 100 mg | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Voglibose | Phase 3 | Diabetes Mellitus, Non-Insulin-Dependent | - | - |
ER-niacin | Phase 3 | Primary Hypercholesterolaemia | - | - |
MK-1293 | Phase 3 | Type 1 Diabetes Mellitus | - | - |
CXA-201 and metronidazole | Phase 3 | Complicated Intra-abdominal Infection | - | - |
Bisoprolol/Amlodipine (Bisoprolol failed group) | Phase 3 | Hypertension | - | - |
PAR-101/OPT-80 | Phase 3 | Clostridium Infections | - | - |
Everolimus | Phase 3 | Metastatic Breast Cancer | - | - |
ZOSTAVAX™ | Phase 3 | Herpes Zoster | - | - |
cetuximab + cisplatin + vinorelbine | Phase 3 | Non Small Cell Lung Cancer (NSCLC) | - | - |
sitagliptin 100 mg q.d./metformin ≥ 1500 mg/day | Phase 3 | Type 2 Diabetes Mellitus (T2DM) | - | - |
Ribavirin (RBV) | Phase 3 | Hepatitis C, Chronic | - | - |
ER niacin (+) laropiprant (ERN/LRPT) | Phase 3 | Dyslipidemia | - | - |
Vancomycin (or equivalent) | Phase 3 | Acute Hematogenous Osteomyelitis | - | - |
Palbociclib | Phase 3 | Renal Cell Carcinoma | - | - |
MK0966; Rofecoxib / Duration of Treatment: 156 weeks | Phase 3 | Colorectal Adenoma | - | - |
Elbasvir | Phase 3 | Hepatitis C | - | - |
V260 | Phase 3 | Rotavirus Gastroenteritis | - | - |
Vericiguat tablet | Phase 3 | Heart Failure | - | - |
Pegylated interferon alfa-2b (SCH 54031) | Phase 3 | Hepatitis C, Chronic | - | - |
MK-8591A | Phase 3 | HIV-1 Infection | - | - |
Prevenar 13™ | Phase 3 | Pneumococcal Infections | - | - |
Imipenem | Phase 3 | Bacterial Pneumonia | - | - |
RotaTeq™ - Rotavirus Vaccine, Live, Oral, Pentavalent | Phase 3 | Vomiting | - | - |
Zanzalintinib | Phase 3 | Renal Cell Carcinoma | - | - |
methotrexate | Phase 3 | Psoriasis | - | - |
5-FU | Phase 3 | Metastatic Esophageal Squamous Cell Carcinoma | - | - |
Vorinostat | Phase 3 | Mesothelioma | - | - |
Oxaliplatin | Phase 3 | Colorectal Neoplasms | - | - |
rolofylline | Phase 3 | Heart Failure, Congestive | - | - |
Patritumab Deruxtecan | Phase 3 | Malignant Neoplasm | - | - |
Gardasil | Phase 3 | Papillomavirus Infections | - | - |
Cetrorelix acetate | Phase 3 | Polycystic Ovarian Syndrome | - | - |
MK0966 / Duration of Treatment: 1 Days | Phase 3 | Pain, Postoperative Arthroscopy | - | - |
RotaTeq (V260) | Phase 3 | Prevention of Rotavirus Gastroenteritis in Infants and Children Caused by Serotypes G1, G2, G3, G4, and G9 | - | - |
Aprepitant | Phase 3 | Post-operative Nausea | - | - |
Frespaciguat | Phase 3 | Pulmonary Hypertension | - | - |
Pembrolizumab/Vibostolimab | Phase 3 | Lung Neoplasms | - | - |
caspofungin acetate | Phase 3 | Fungal Infection | - | - |
MK0826, ertapenem sodium | Phase 3 | Infections | - | - |
Pembrolizumab (+) Berahyaluronidase alfa | Phase 3 | Lung Cancer | - | - |
Paclitaxel | Phase 3 | Metastatic Non-Small Cell Lung Cancer | - | - |
MK-6072 | Phase 3 | Clostridium Difficile Infection | - | - |
Gliclazide | Phase 3 | Type 2 Diabetes Mellitus | - | - |
MK-0524A | Phase 3 | Hypercholesteremia | - | - |
Supportive care measures | Phase 3 | Non-small Cell Lung Cancer (NSCLC) | - | - |
ZOSTAVAX™ (concomitant) | Phase 3 | Herpes Zoster | - | - |
Doxorubicin | Phase 3 | Breast Neoplasms | - | - |
MK0974 50 mg | Phase 3 | Migraine | - | - |
Vitamin D3 | Phase 3 | Osteoporosis | - | - |
MK0869, aprepitant / Duration of Treatment: 3 days | Phase 3 | Nausea | - | - |
neostigmine and glycopyrrolate or atropine | Phase 3 | Neuromuscular Blockade | - | - |
INS365 Ophthalmic Solution | Phase 3 | Keratoconjunctivitis Sicca | - | - |
Glipizide | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
Dexamethasone | Phase 3 | Metastatic Castration-resistant Prostate Cancer (mCRPC) | - | - |
M-M-R™II manufactured with recombinant Human Albumin (rHA) and VARIVAX® | Phase 3 | Measles | - | - |
regorafenib | Phase 3 | Colorectal Cancer | - | - |
sitagliptin phosphate (+) metformin hydrochloride | Phase 3 | Type 2 Diabetes Mellitus | - | - |
V110, pneumococcal vaccine polyvalent | Phase 3 | Healthy | - | - |
Sofosbuvir | Phase 3 | Hepatitis C | - | - |
Reformulated Raltegravir | Phase 3 | HIV Infection | - | - |
Background PAH Therapy | Phase 3 | Pulmonary Arterial Hypertension | - | - |
boceprevir (SCH 503034) | Phase 3 | Chronic Hepatitis C | - | - |
BIC/FTC/TAF | Phase 3 | HIV-1 Infection | - | - |
MK0991, caspofungin acetate / Duration of Treatment: | Phase 3 | Fungal Infection | - | - |
daptomycin | Phase 3 | Pneumonia, Bacterial | - | - |
Ertugliflozin 5 mg | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Carboplatin | Phase 3 | Carcinoma, Squamous Cell, Non-small-cell Lung | - | - |
alvimopan | Phase 3 | Ileus | - | - |
pembrolizumab | Phase 3 | Non-small Cell Lung Cancer | - | - |
Nemtabrutinib | Phase 3 | Chronic Lymphocytic Leukemia | - | - |
Prevnar 13™ | Phase 3 | Pneumococcal Infections | - | - |
Zoster Vaccine, Live (Zostavax™) | Phase 3 | Shingles | - | - |
DOR/ISL | Phase 3 | HIV Infection | - | - |
Rocuronium bromide (Org 9426) | Phase 3 | Muscle Relaxation | - | - |
Rocuronium 0.6 mg/kg intubating dose | Phase 3 | Anesthesia | - | - |
Rocuronium bolus maintenance | Phase 3 | Anesthesia | - | - |
V114 | Phase 3 | Pneumococcal Infections | - | - |
sitagliptin phosphate | Phase 3 | Type 2 Diabetes | - | - |
Infliximab | Phase 3 | Psoriasis | - | - |
Ertugliflozin 15 mg | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Metformin IR | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Zoster Vaccine Live | Phase 3 | Herpes Zoster | - | - |
ER niacin/laropiprant | Phase 3 | Diabetes Mellitus Type 2 | - | - |
Grazoprevir + Elbasvir | Phase 3 | Hepatitis C Infection | - | - |
Cetuximab + concomitant boost radiotherapy | Phase 3 | Squamous Cell Carcinoma of the Head and Neck | - | - |
L50/H12.5/A5 | Phase 3 | Hypertension | - | - |
MK0826, /Duration of Treatment : 8 Weeks | Phase 3 | Complicated Intra-Abdominal Infections | - | - |
bortezomib | Phase 3 | Multiple Myeloma | - | - |
sugammadex | Phase 3 | Neuromuscular Blockade | - | - |
Tedizolid Phophate | Phase 3 | Skin Diseases, Infectious | - | - |
MK0507A, dorzolamide hydrochloride (+) timolol maleate | Phase 3 | Glaucoma | - | - |
MK0217A, alendronate sodium (+) cholecalciferol / Duration of Treatment: 24 weeks | Phase 3 | Osteoporosis | - | - |
raltegravir potassium | Phase 3 | HIV Infections | - | - |
rotavirus vaccine, live, oral, pentavalent | Phase 3 | Rotavirus Infections | - | - |
Grazoprevir/Elbasvir | Phase 3 | Hepatitis C | - | - |
Temozolomide | Phase 3 | Glioblastoma | - | - |
Cisplatin | Phase 3 | Gastric Neoplasms | - | - |
laropiprant/niacin (MK0524A) | Phase 3 | Hypercholesterolemia | - | - |
Sitagliptin | Phase 3 | Type 2 Diabetes Mellitus | - | - |
9vHPV vaccine | Phase 3 | Papillomavirus Infections | - | - |
Gonal-f® | Phase 3 | Assisted Reproductive Techniques | - | - |
Ibrutinib | Phase 3 | Chronic Lymphocytic Leukemia | - | - |
COL-1620 | Phase 3 | Luteal Hormone Supplementation in In-vitro Fertilization | - | - |
V441, diptheria, tetanus, acellular pertussis, inactivated poliomyelitis, hepatitis B (recombinant), & Haemophilus influenza type b conjugate vaccine | Phase 3 | Diphtheria | - | - |
V501 | Phase 3 | Human | - | - |
losartan potassium (+) hydrochlorothiazide | Phase 3 | Hypertension | - | - |
Preladenant | Phase 3 | Parkinson Disease | - | - |
Opevesostat | Phase 3 | Prostate Cancer Metastatic | - | - |
Sotatercept | Phase 3 | Pulmonary Arterial Hypertension | - | - |
Bezlotoxumab | Phase 3 | Clostridium Difficile Infection | - | - |
PCV20 | Phase 3 | Pneumococcal Infection | - | - |
Ertugliflozin | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Peginterferon alfa-2b | Phase 3 | Carcinoma, Hepatocellular | - | - |
Ipragliflozin | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Rocuronium bromide | Phase 3 | Anesthesia | - | - |
Pemetrexed | Phase 3 | Carcinoma, Nonsquamous Non-small-cell Lung | - | - |
IMI/REL | Phase 3 | Suspected or Documented Gram-negative Bacterial Infection | - | - |
MK0966, rofecoxib | Phase 3 | Postoperative Pain | - | - |
Posaconazole oral suspension | Phase 3 | Mycoses | - | - |
Follitropin alfa liquid formulation | Phase 3 | Infertility | - | - |
Micronised Progesterone | Phase 3 | Infertility | - | - |
Imipenem+Cilastatin/Relebactam | Phase 3 | Complicated Intra-abdominal Infection | - | - |
Doravirine | Phase 3 | HIV-1 | - | - |
Telcagepant | Phase 3 | Migraine | - | - |
Lenvatinib | Phase 3 | Non-small Cell Lung Cancer | - | - |
V503 (9-valent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] vaccine) | Phase 3 | Human Papillomavirus Infection | - | - |
V116 | Phase 3 | Pneumococcal Infection | - | - |
Omarigliptin | Phase 3 | Type 2 Diabetes Mellitus | - | - |
MR Prednisone | Phase 3 | Rheumatoid Arthritis | - | - |
Pembrolizumab 200 mg | Phase 3 | Non-Small-Cell Lung Carcinoma | - | - |
Enfortumab vedotin (EV) | Phase 3 | Bladder Cancer | - | - |
Cetuximab | Phase 3 | Gastric Cancer | - | - |
Combination of (a) pegylated interferon alfa-2b and (b) rebetol | Phase 3 | Liver Transplantation | - | - |
Gefapixant 45 mg twice daily (BID) | Phase 3 | Chronic Cough | - | - |
Gefapixant | Phase 3 | Chronic Cough | - | - |
Indinavir sulfate | Phase 3 | HIV Infections | - | - |
Ridaforolimus | Phase 3 | Sarcoma | - | - |
V503 | Phase 3 | Papillomavirus Infections | - | - |
Saizen® | Phase 3 | Fibromyalgia | - | - |
Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live | Phase 3 | Measles | - | - |
mFOLFOX6 | Phase 3 | Colorectal Carcinoma | - | - |
Sitagliptin (MK0431) | Phase 3 | Diabetes Mellitus, Type II | - | - |
Cisplatin 100 mg/m^2 | Phase 3 | Head and Neck Neoplasms | - | - |
Efavirenz | Phase 3 | HIV Infections | - | - |
Enlicitide Decanoate | Phase 3 | Hypercholesterolemia | - | - |
Odanacatib | Phase 3 | Osteoporosis Postmenopausal | - | - |
pegylated interferon alpha-2b | Phase 3 | Hepatitis B, Chronic | - | - |
V419 | Phase 3 | Bacterial Infections | - | - |
Suvorexant | Phase 3 | Insomnia | - | - |
Rocuronium | Phase 3 | Anesthesia, General | - | - |
Gemcitabine | Phase 3 | Biliary Tract Carcinoma | - | - |
vaniprevir | Phase 3 | Hepatitis C, Chronic | - | - |
VARIVAX® PE34 Process | Phase 3 | Varicella | - | - |
Belzutifan | Phase 3 | Renal Cell Carcinoma | - | - |
Vorapaxar 2.5 mg | Phase 3 | Cerebral Infarction | - | - |
Rocurium | Phase 3 | Anesthesia, General | - | - |
Capecitabine | Phase 3 | Advanced/Metastatic Gastroesophageal Adenocarcinoma | - | - |
100 mg clindamycin /800 mg ketoconazole vaginal ovule | Phase 3 | Vaginosis, Bacterial | - | - |
QIV | Phase 3 | Pneumonia, Pneumococcal | - | - |
Acetaminophen/Paracetamol | Phase 3 | Migraine Disorders | - | - |
Ipilimumab | Phase 3 | Melanoma | - | - |
Alviompan | Phase 3 | Bowel Dysfunction | - | - |
taranabant | Phase 3 | Smoking | - | - |
Nab-paclitaxel | Phase 3 | Non-small Cell Lung Cancer | - | - |
V221, measles, mumps, rubella and varicella (Oka/Merck) virus vaccine live / Duration of Treatment: 12 weeks | Phase 3 | Measles | - | - |
V501, Gardasil, Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine / Duration of Treatment : 4 Years | Phase 3 | Cervical Cancer | - | - |
Enfortumab Vedotin | Phase 3 | Urinary Bladder Cancer, Muscle-invasive | - | - |
Cladribine Low Dose | Phase 3 | Generalized Myasthenia Gravis | - | - |
Metformin | Phase 3 | Diabetes Mellitus | - | - |
Colistimethate sodium (CMS) | Phase 3 | Bacterial Infections | - | - |
Acarbose | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Fluorouracil (5-FU) | Phase 3 | Urinary Bladder Neoplasms | - | - |
Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine | Phase 3 | HPV Infections | - | - |
2XP HEPTAVAX™-II SC | Phase 3 | Hepatitis B | - | - |
Abiraterone acetate | Phase 3 | Prostatic Neoplasms | - | - |
DOR | Phase 3 | HIV-1 Infection | - | - |
denufosol tetrasodium (INS37217) Inhalation Solution | Phase 3 | Cystic Fibrosis | - | - |
succinylcholine | Phase 3 | Neuromuscular Blockade | - | - |
MK-1084 | Phase 3 | Colon Adenocarcinoma | - | - |
peg-IFN | Phase 3 | Hepatitis C, Chronic | - | - |
V503 Vaccine | Phase 3 | Papillomavirus Infections | - | - |
Saizen® A | Phase 3 | Children Born With Serious Intra-uterine Growth Retardation | - | - |
vinflunine | Phase 3 | Urothelial Cancer | - | - |
Modified Process Hepatitis B Vaccine | Phase 3 | Hepatitis B | - | - |
MK0557 | Phase 3 | Obesity | - | - |
Pembrolizumab Formulated with Berahyaluronidase Alfa | Phase 3 | Metastatic Non-small Cell Lung Cancer | - | - |
Pneumovax™ 23 | Phase 3 | Pneumococcal Infections | - | - |
Posaconazole | Phase 3 | Mycoses | - | - |
Metformin - Rescue | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
Infanrix® hexa | Phase 3 | Varicella | - | - |
IV Tulisokibart | Phase 3 | Crohn's Disease | - | - |
Daptomycin 4 mg/kg | Phase 3 | Staphylococcal Infection | - | - |
Gonalef® (Follitropin alfa) | Phase 3 | Infertility | - | - |
Fluconazole | Phase 3 | Leukopenia | - | - |
MK0826, ertapenem sodium / Duration of Treatment - 24 weeks | Phase 3 | Foot Infections in Diabetic Patients | - | - |
Naproxen | Phase 3 | Endometriosis-related Pain | - | - |
fidaxomicin | Phase 3 | Clostridium Difficile-Associated Diarrhea (CDAD) | - | - |
losartan potassium | Phase 3 | Hypertension | - | - |
anacetrapib | Phase 3 | Coronary Heart Disease (CHD) | - | - |
Suvorexant Low Dose (LD) | Phase 3 | Primary Insomnia | - | - |
dorzolamide hydrochloride (+) timolol maleate | Phase 3 | Glaucoma | - | - |
rofecoxib | Phase 3 | Prostate Cancer | - | - |
ProQuad® | Phase 3 | Measles | - | - |
MK1903 | Phase 2 | Dyslipidemia | - | - |
Single low dose cyclophosphamide | Phase 2 | Carcinoma, Non-Small-Cell Lung | - | - |
denufosol tetrasodium Inhalation Solution | Phase 2 | Cystic Fibrosis | - | - |
CXA-101 | Phase 2 | Complicated Urinary Tract Infection | - | - |
ATX-MS-1467 | Phase 2 | Multiple Sclerosis | - | - |
MK-8189 | Phase 2 | Schizophrenia, Acute Episode | - | - |
MK0524A, niacin (+) laropiprant / Duration of Treatment : 4 Weeks | Phase 2 | Hypercholesterolemia | - | - |
pegylated interferon | Phase 2 | Chronic Hepatitis C | - | - |
Pegylated Interferon (peg-IFN) | Phase 2 | Hepatitis C | - | - |
MK-1029 150 mg | Phase 2 | Asthma | - | - |
Multiple low dose cyclophosphamide | Phase 2 | Multiple Myeloma | - | - |
Islatravir | Phase 2 | HIV-1 Infection | - | - |
Recombinant human growth hormone (r-hGH) | Phase 2 | Hypochondroplasia | - | - |
Lonafarnib | Phase 2 | Breast Cancer | - | - |
tretinoin | Phase 2 | Acute Myeloid Leukemia | - | - |
denufosol tetrasodium (INS37217) | Phase 2 | Cystic Fibrosis | - | - |
OPT-80 | Phase 2 | Diarrhea | - | - |
Dalantercept plus sorafenib | Phase 2 | Advanced Adult Hepatocellular Carcinoma | - | - |
Stavudine | Phase 2 | HIV Infections | - | - |
Ifinatamab Deruxtecan (I-DXd) | Phase 2 | Small Cell Lung Cancer | - | - |
Nelfinavir mesylate | Phase 2 | HIV Infections | - | - |
Dalotuzumab | Phase 2 | Carcinoma, Non-small-cell Lung | - | - |
MK-8777 | Phase 2 | Depression | - | - |
Risperidone | Phase 2 | Schizophrenia | - | - |
ARQ 197 | Phase 2 | Pancreatic Neoplasms | - | - |
Boserolimab | Phase 2 | Small Cell Lung Cancer | - | - |
r-hFSH | Phase 2 | Infertility | - | - |
2 NRTIs | Phase 2 | Human Immunodeficiency Virus (HIV) Infection | - | - |
ARQ 501 | Phase 2 | Cancer | - | - |
Robatumumab | Phase 2 | Colorectal Cancer | - | - |
ADL5945 0.1 mg | Phase 2 | Opioid Induced Constipation | - | - |
MK0431, sitagliptin phosphate / Duration of Treatment: 21 Weeks | Phase 2 | Diabetes Mellitus, Type II | - | - |
PegIFN-2b | Phase 2 | HIV Infections | - | - |
M5717 330 mg | Phase 2 | Acute Malaria | - | - |
RSV A Memphis 37b | Phase 2 | Respiratory Syncytial Virus | - | - |
MK0826, ertapenem sodium /Duration of Treatment: 14 Days | Phase 2 | Urinary Tract Infections | - | - |
PegIntron (peginterferon alfa-2b) | Phase 2 | Hepatitis C, Chronic | - | - |
AR51 (12, 10) | Phase 2 | Bacterial Infections; Virus Diseases | - | - |
Relebactam 250 mg | Phase 2 | Intra-abdominal Infections | - | - |
Vibostolimab | Phase 2 | Melanoma | - | - |
MK0493 | Phase 2 | Obesity | - | - |
MK0812 / Duration of Treatment: 12 Weeks | Phase 2 | Arthritis, Rheumatoid | - | - |
Atorvastatin/niacin extended-release | Phase 2 | Carotid Atherosclerosis | - | - |
EV | Phase 2 | Bladder Cancer | - | - |
Rebif | Phase 2 | Multiple Sclerosis | - | - |
INS37217 Nasal Spray | Phase 2 | Perennial Allergic Rhinitis | - | - |
MK0974 | Phase 2 | Migraine | - | - |
MK0777 | Phase 2 | Generalized Anxiety Disorder | - | - |
diphenhydramine | Phase 2 | Carcinoma, Non-Small-Cell Lung | - | - |
Ruzasvir | Phase 2 | Hepatitis C | - | - |
MK-0482 | Phase 2 | Carcinoma, Non-Small-Cell Lung | - | - |
Uprifosbuvir | Phase 2 | Hepatitis C | - | - |
MK-8616 | Phase 2 | Neuromuscular Blockade | - | - |
Benznidazole | Phase 2 | Chagas Disease | - | - |
Pneumococcal Conjugate Vaccine (V114) | Phase 2 | Pneumococcal Infections | - | - |
MK-0873 | Phase 2 | Rheumatoid Arthritis | - | - |
Matuzumab | Phase 2 | Esophageal Cancer | - | - |
V114 Aluminum-adjuvanted | Phase 2 | Pneumococcal Infections | - | - |
Gefitinib | Phase 2 | Non-small Cell Lung Carcinoma | - | - |
Vibostolimab/Pembrolizumab | Phase 2 | Carcinoma, Renal Cell | - | - |
V504 | Phase 2 | Cervical Cancer | - | - |
MK-3120 | Phase 2 | Urothelial Carcinoma | - | - |
MK0431, sitagliptin phosphate / Duration of Treatment: 12 Weeks | Phase 2 | Type 2 Diabetes Mellitus | - | - |
Vicriviroc maleate | Phase 2 | HIV | - | - |
Navarixin | Phase 2 | Solid Tumors | - | - |
Daptomycin for Injection | Phase 2 | Bacteremia | - | - |
Exemestane | Phase 2 | Breast Neoplasms | - | - |
imipenem/cilastatin 500 mg | Phase 2 | Urinary Tract Infections | - | - |
UFOX + Cetuximab | Phase 2 | Previously Untreated Metastatic Colorectal Cancer | - | - |
SCH 619734 | Phase 2 | Cough | - | - |
Ritonavir | Phase 2 | HIV Infections | - | - |
Ertugliflozin 25 mg | Phase 2 | Diabetes Mellitus, Type 2 | - | - |
MK8141 | Phase 2 | Hypertension | - | - |
cetuximab, cisplatin | Phase 2 | Breast Neoplasm | - | - |
Raludotatug Deruxtecan (R-DXd) | Phase 2 | Gastrointestinal Cancer | - | - |
Interferon beta-1a | Phase 2 | Alzheimer's Disease | - | - |
MK0639, indinavir sulfate / Duration of Treatment: 48 Weeks | Phase 2 | HIV Infections | - | - |
Tepotinib | Phase 2 | Non-small Cell Lung Cancer | - | - |
V114 Medium Dose | Phase 2 | Pneumococcal Infections | - | - |
V181 High-Potency Level | Phase 2 | Dengue Disease | - | - |
MK-3795 | Phase 2 | VHL Gene Mutation | - | - |
ADL5747 | Phase 2 | Osteoarthritis of the Knee | - | - |
Prednisolone | Phase 2 | Lymphoma, Large B-Cell, Diffuse | - | - |
cyclophosphamide (CPA) | Phase 2 | Rectal Cancer | - | - |
V114 Lot 1 | Phase 2 | Pneumococcal Infections | - | - |
Biltricide (racemate praziquantel) oral tablets | Phase 2 | Schistosomiasis | - | - |
CXA-101/ tazobactam and metronidazole | Phase 2 | Complicated Intra-abdominal Infection | - | - |
TR-701 200 mg | Phase 2 | Skin Diseases, Infectious | - | - |
luspatercept | Phase 2 | B-Thalassemia | - | - |
Emfilermin, recombinant human leukemia inhibitory factor (r-hLIF) | Phase 2 | Infertility Implantation Failure | - | - |
SCH 900636 | Phase 2 | Depressive Disorders | - | - |
MK-8690 | Phase 2 | Colitis Ulcerative | - | - |
adavosertib | Phase 2 | Ovarian Cancer | - | - |
MK0822A | Phase 2 | Vitamin D Deficiency | - | - |
MK0633 | Phase 2 | Atherosclerosis | - | - |
Pegylated Lyposomal Doxorubicin | Phase 2 | Breast Neoplasm | - | - |
MK0782 | Phase 2 | Stomach Ulcer | - | - |
MK0249 | Phase 2 | Attention-Deficit/Hyperactivity Disorder (ADHD) | - | - |
EMD 525797 250 mg | Phase 2 | Metastatic Colorectal Cancer | - | - |
Letermovir oral granules | Phase 2 | Cytomegalovirus (CMV) Infection | - | - |
Cilengitide 2000 mg once weekly | Phase 2 | Squamous Cell Cancer | - | - |
TR701 FA | Phase 2 | Major Cutaneous Abscess | - | - |
Doravirine, Tenofovir, Lamivudine - Blinded | Phase 2 | HIV-1 | - | - |
MK-8435 (Org 25935) 4-8 mg | Phase 2 | Schizophrenia | - | - |
V940 | Phase 2 | Squamous Non-small Cell Lung Cancer | - | - |
PR51 (3, 10) | Phase 2 | Bacterial Infections; Virus Diseases | - | - |
R-DXD | Phase 2 | Lung Neoplasm | - | - |
Efinopegdutide | Phase 2 | Metabolic Dysfunction-Associated Steatotic Liver Disease | - | - |
Raltegravir Film-coated Tablet | Phase 2 | HIV Infection | - | - |
MK-6096 | Phase 2 | Migraine | - | - |
Pembrolizumab/vibostolimab coformulation | Phase 2 | Bladder Cancer | - | - |
Navarixin 10 mg | Phase 2 | Psoriasis | - | - |
PRA023 IV | Phase 2 | Crohn Disease | - | - |
irinotecan hydrochloride | Phase 2 | Metastatic Colorectal Cancer | - | - |
Efinopegdutide 20 mg/mL | Phase 2 | Nonalcoholic Fatty Liver Disease | - | - |
MK0736 | Phase 2 | Hypertension | - | - |
MK-0941 | Phase 2 | Type 2 Diabetes Mellitus | - | - |
Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 20/40/40/20 | Phase 2 | Papillomavirus Infections | - | - |
Olaparib 400 mg | Phase 2 | Metastatic Castration-Resistant Prostate Cancer | - | - |
teicoplanin | Phase 2 | Osteomyelitis | - | - |
Miransertib | Phase 2 | PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome (PS) | - | - |
Ramucirumab | Phase 2 | Gastroesophageal Junction | - | - |
Vaniprevir 600 mg b.i.d. | Phase 2 | Hepatitis C, Chronic | - | - |
rolofyline | Phase 2 | Congestive Heart Failure | - | - |
MK0429 | Phase 2 | Post-Menopausal Osteoporosis | - | - |
MK0686 | Phase 2 | Pain, Postoperative | - | - |
MK-0893 | Phase 2 | Diabetes Mellitus, Type 2 | - | - |
IDX719 | Phase 2 | Hepatitis C, Chronic | - | - |
Sitagliptin 25 mg | Phase 2 | Glucose Intolerance | - | - |
S-1 | Phase 2 | Gastric Cancer | - | - |
ADL5859 30 mg | Phase 2 | Acute Pain | - | - |
SCH 900271 15mg | Phase 2 | Primary Hypercholesterolemia | - | - |
ZA | Phase 2 | Breast Cancer | - | - |
MK633 | Phase 2 | Chronic Obstructive Pulmonary Disease (COPD) | - | - |
L-756423 | Phase 2 | HIV Infections | - | - |
MK3207- 2.5 mg | Phase 2 | Migraine | - | - |
timolol/dorzolamide combination | Phase 2 | Glaucoma | - | - |
Doxorubicin hydrochloride | Phase 2 | Breast Neoplasms | - | - |
vinblastine | Phase 2 | Hodgkin Lymphoma | - | - |
Esmeron® | Phase 2 | Neuromuscular Blockade | - | - |
r-FSH | Phase 2 | Ovarian Stimulation | - | - |
MK5757 | Phase 2 | Schizophrenia | - | - |
MK2295 | Phase 2 | Pain, Postoperative | - | - |
Enclitide Chloride | Phase 2 | Hypercholesterolemia | - | - |
NM283 plus Peg-IFNα-2a | Phase 2 | Chronic Hepatitis C | - | - |
Gefapixant 50 mg | Phase 2 | Asthma | - | - |
MK-6213 | Phase 2 | Hypercholesterolemia | - | - |
coformulation pembrolizumab/quavonlimab | Phase 2 | Small Cell Lung Carcinoma | - | - |
MK-2060 | Phase 2 | End-Stage Renal Disease | - | - |
IDX184 | Phase 2 | Chronic Hepatitis C Infection | - | - |
Pleconaril | Phase 2 | Asthma | - | - |
Gocatamig | Phase 2 | Small-Cell Lung Cancer | - | - |
Quavonlimab | Phase 2 | Advanced Solid Tumors | - | - |
ATRA | Phase 2 | Melanoma | - | - |
Samatasvir | Phase 2 | Chronic Hepatitis C Virus | - | - |
MK-1167 | Phase 2 | Alzheimer Disease | - | - |
SCH 530348 | Phase 2 | Arterial Obstructive Diseases | - | - |
MK-1200 | Phase 2 | Advanced Solid Tumors | - | - |
MK-2214 | Phase 2 | Early Alzheimer's Disease | - | - |
Epinastine Nasal Spray | Phase 2 | Seasonal Allergic Rhinitis | - | - |
Posaconazole IV | Phase 2 | Invasive Aspergillosis | - | - |
Grazoprevir (GZR) | Phase 2 | Hepatitis C Virus | - | - |
SCH 727965 | Phase 2 | Breast Neoplasms | - | - |
V114-A | Phase 2 | Pneumococcal Infections | - | - |
IFN beta 1a 44 mcg TIW | Phase 2 | Multiple Sclerosis | - | - |
Pegylated Liposomal Doxorubicin | Phase 2 | Breast Neoplasm | - | - |
Avelumab | Phase 2 | Squamous Non-Small Cell Lung Cancer | - | - |
MK-4830 | Phase 2 | Carcinoma, Non-Small-Cell Lung | - | - |
Dabrafenib | Phase 2 | Melanoma | - | - |
Ulevostinag | Phase 2 | Head and Neck Squamous Cell Carcinoma (HNSCC) | - | - |
Tepotinib 300 mg | Phase 2 | Carcinoma, Hepatocellular | - | - |
I-DXd | Phase 2 | Esophageal Squamous Cell Carcinoma | - | - |
zoster vaccine live (Oka/Merck) | Phase 2 | Shingles | - | - |
Avastin | Phase 2 | High-grade Serous Ovarian Carcinoma | - | - |
Raludotatug Deruxtecan | Phase 2 | Ovarian Cancer Recurrent | - | - |
MK0524A, niacin (+) laropiprant / Duration of Treatment: 17 Weeks | Phase 2 | Flushing | - | - |
Atacicept | Phase 2 | Rheumatoid Arthritis | - | - |
VigantOL oil plus interferon beta-1a (Rebif) | Phase 2 | Relapsing-Remitting Multiple Sclerosis | - | - |
Coformulation favezelimab/pembrolizumab | Phase 2 | Esophageal Squamous Cell Carcinoma (ESCC) | - | - |
Vibegron | Phase 2 | Urinary Bladder, Overactive | - | - |
ridaforolimus (MK8669) | Phase 2 | Prostate Cancer | - | - |
SCH 56592 | Phase 2 | Onychomycosis | - | - |
Org 34517 | Phase 2 | Depression | - | - |
MK-1029 | Phase 2 | Asthma | - | - |
MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment 6 Months | Phase 2 | B-cell Lymphoma | - | - |
Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate | Phase 2 | HIV-1 Infection | - | - |
ARQ 501 in combination with gemcitabine | Phase 2 | Pancreatic Cancer | - | - |
Coformulated favezelimab/pembrolizumab | Phase 2 | Metastatic Urothelial Carcinoma | - | - |
Fosaprepitant | Phase 2 | Chemotherapy-induced Nausea and Vomiting | - | - |
MK0524A, /Duration of Treatment : 8 Weeks | Phase 2 | Flushing | - | - |
Rolapitant Dose 1 | Phase 2 | Postoperative Nausea and Vomiting | - | - |
val-mCyd | Phase 2 | Chronic Hepatitis C | - | - |
V205C, measles, mumps, and rubella virus vaccine live | Phase 2 | Measles | - | - |
MK0359 | Phase 2 | Pulmonary Disease, Chronic Obstructive | - | - |
Gefapixant 45 mg | Phase 2 | Chronic Cough | - | - |
Farnesyl Protein Transferase Inhibitor | Phase 2 | Leukemia | - | - |
Grazoprevir/Elbasvir FDC | Phase 2 | Hepatitis C | - | - |
ADL5859 | Phase 2 | Peripheral Neuropathy | - | - |
MK2461 | Phase 2 | Neoplasm | - | - |
MK-5442 | Phase 2 | Osteoporosis | - | - |
Donepezil | Phase 2 | Alzheimer's Disease | - | - |
MK0524 | Phase 2 | Seasonal Allergies | - | - |
MK-0634 50 mg | Phase 2 | Urinary Incontinence | - | - |
MK0991, caspofungin acetate | Phase 2 | Aspergillosis | - | - |
SCH 486757 | Phase 2 | Cough | - | - |
Tecemotide (L-BLP25) | Phase 2 | Lung Neoplasms | - | - |
measles, mumps, and rubella virus vaccine live | Phase 2 | Measles | - | - |
peginterferon alfa 2b | Phase 2 | Hepatitis C, Chronic | - | - |
Gefapixant 100 mg | Phase 2 | Refractory Chronic Cough | - | - |
TS-1 | Phase 2 | Gastric Cancer | - | - |
Vecuronium | Phase 2 | Anesthesia, General | - | - |
medroxyprogesterone acetate tablets OR megestrol acetate | Phase 2 | Endometrial Cancer | - | - |
AS900672-Enriched 50 microgram (mcg) | Phase 2 | Infertility | - | - |
Vicriviroc 30 mg | Phase 2 | HIV Infections | - | - |
valopicitabine | Phase 2 | Chronic Hepatitis C | - | - |
MK0677 | Phase 2 | Alzheimer's Disease | - | - |
Cilengitide | Phase 2 | Carcinoma, Non-Small-Cell Lung | - | - |
Rescue | Phase 2 | Type II Diabetes Mellitus | - | - |
ridaforolimus + dalotuzumab | Phase 2 | Breast Cancer | - | - |
ARQ 197 plus erlotinib | Phase 2 | Metastatic Non-Small Cell Lung Cancer | - | - |
ecallantide | Phase 2 | Bloodloss | - | - |
Recombinant human follicle stimulating hormone (r-hFSH) | Phase 2 | Infertility | - | - |
MK0991, caspofungin acetate/Duration of Treatment: variable | Phase 2 | Candidiasis | - | - |
Posaconazole IV 6 mg/kg | Phase 2 | Invasive Fungal Infection | - | - |
ibuprofen | Phase 2 | Migraine | - | - |
Pembrolizumab (neoadjuvant) | Phase 2 | Lung Neoplasm Malignant | - | - |
MK0518 | Phase 2 | HIV Infections | - | - |
ADL5945 0.25 mg | Phase 2 | Constipation | - | - |
TRUVADA® | Phase 2 | HIV Infections | - | - |
M5717 60 mg | Phase 2 | Malaria Infection | - | - |
Antihistamine | Phase 2 | Esophageal Squamous Cell Carcinoma | - | - |
MK-5684 | Phase 2 | Malignant Neoplasm | - | - |
FOLFIRI | Phase 2 | Metastatic Colorectal Cancer | - | - |
Ertugliflozin 1 mg | Phase 2 | Diabetes Mellitus, Type 2 | - | - |
Oral testosterone undecanoate (Andriol) | Phase 2 | Hypogonadism | - | - |
M5049 low dose | Phase 2 | Systemic Lupus Erythematosus | - | - |
Azithromycin ophthalmic solution, 1% | Phase 2 | Blepharitis | - | - |
Vorapaxar | Phase 2 | Atherosclerosis | - | - |
Docetetaxel | Phase 2 | Carcinoma, Non-Small-Cell Lung | - | - |
Itraconazole | Phase 2 | Chronic Hepatitis C | - | - |
Pegylated Interferon Alfa | Phase 2 | Chronic Hepatitis C | - | - |
KW-3902IV | Phase 2 | Heart Failure, Congestive | - | - |
Favezelimab | Phase 2 | Advanced Non-Small Cell Lung Cancer | - | - |
tildrakizumab | Phase 2 | Psoriasis | - | - |
SCH 900538 | Phase 2 | Seasonal Allergic Rhinitis | - | - |
SCH 497079 | Phase 2 | Obesity | - | - |
EBR/GZR FDC Tablet | Phase 2 | HCV Infection | - | - |
Pertuzumab | Phase 2 | Breast Neoplasms | - | - |
epinastine 0.1% | Phase 2 | Allergic Rhinitis | - | - |
MK0916 | Phase 2 | Diabetes Mellitus, Type 2 | - | - |
V160 | Phase 2 | Cytomegalovirus (CMV) Infections | - | - |
MK-2140 (zilovertamab vedotin) | Phase 2 | Relapsed or Refractory Diffuse Large B-Cell Lymphoma | - | - |
Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (V501) | Phase 2 | HPV Infections | - | - |
MK-8998 | Phase 2 | Schizophrenia | - | - |
Cabazitaxel | Phase 2 | Prostatic Neoplasms, Castration-Resistant | - | - |
L-dopa | Phase 2 | Parkinson Disease | - | - |
MK0364 | Phase 2 | Obesity | - | - |
Sacituzumab Tirumotecan (sac-TMT) | Phase 2 | Gastroesophageal Junction | - | - |
Hepatitis C, Chronic
1 drug in this indication
Breast Cancer
1 drug in this indication
Dyslipidemia
1 drug in this indication
Hepatitis C
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)